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Abstract 
 Endogenous glucocorticoid (GC) steroids are lipophilic hormones secreted 
in response to the hypothalamic-pituitary-adrenal axis. Their anti-inflammatory 
and immunosuppressive potency is the basis for their frequent use in clinical 
applications. Dexamethasone (Dex) is a synthetic GC given to breast cancer 
patients to reduce emetic effects of chemotherapeutic drugs (e.g., paclitaxel (Pac)). 
GCs mediate their effects on cell behaviour through activation of the GC receptor 
(GR). Active GR regulates approximately 10% of the human genome influencing 
numerous physiological and developmental parameters including cell proliferation, 
invasion, migration, and survival. The prevalent use of Dex in breast cancer 
treatment is disconcerting given that little is known about its impact on breast 
cancer cell behaviour. We show that Dex can increase the ability of triple negative 
breast cancer cells to survive, migrate and invade in vitro as well as enhance 
overall metastatic properties (e.g., survival, and/or motility) in vivo. Moreover, 
there is growing evidence that the ability of Dex to promote survival extends to 
protection from chemotherapy-induced cell death. We show that Dex protects 
triple negative and luminal breast cancer cells from Pac-induced apoptosis through 
contrary regulation of nuclear factor kappa B (NFκB) activity. We show that Pac-
activated NFκB upregulates expression of the death receptor Fas and that knock-
down of NFκB abrogates Pac-induced upregulation. Thus, our data supports a role 
for Dex antagonizing Pac through inhibition of Pac-induced NFκB transcription of 
Fas. 	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1.1 Breast cancer 
1.1.1 Canadian breast cancer statistics  
 It is currently estimated (2014), that approximately two in every five Canadians 
will develop cancer at some point in their lives; nearly one in four Canadians will die of 
cancer [1]. Cancer is a collection of diseases and of the (approximate) 200,000 new 
diagnoses of cancer in Canada in 2014, more than half will fall into only one of four 
types: lung, breast, colorectal, and prostate [1]. While men have a slightly higher 
likelihood of developing cancer (45%) compared to women (41%), the most prevalent 
type of cancer in women (breast cancer) has yielded almost triple the number of potential 
years of life lost than has the most common cancer in men (prostate) due to the average 
age at which it typically presents [1]. Breast cancer is the most common type of cancer in 
Canadian women accounting for over 26% percent of the more than 93,000 new cases of 
cancer in women in 2014 [1].   
1.1.2 Breast cancer metastasis 
 While breast cancer starts through formation of a primary tumour at a local site, it 
can eventually metastasize to proximal lymph nodes and/or intravasate into blood vessels 
traveling to distant sites [2]. It is metastasis to distant sites, rather than primary tumours, 
that are the greatest cause of cancer related deaths, accounting for over 90% of cancer 
mortality [2,3]. Nearly 15% of breast cancer patients have aggressive disease and can 
develop metastasis in under three years following diagnosis [2]; the most common distant 
sites of metastasis being liver, lung, and bone [2,3]. Metastasis of breast cancer follows a 
similar pattern as other solid tumours in that several key steps are necessary: 1) the ability 
of tumour cells to survive (elude apoptosis) and proliferate at the primary tumour site; 2) 
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the ability to invade surrounding tissue at the primary site; 3) the ability of the cells to 
migrate in the circulation or neighbouring tissue and 4) attachment and colonization at 
the distant site [4].  
1.1.2.1 Breast cancer metastasis: survival/proliferation 
	  
 Recent studies report that inhibition of apoptotic pathways are a critical 
characteristic of metastatic cancer cells [4], as tumour progression correlates with the loss 
and/or gain of function of pro- and/or anti-apoptotic markers respectively [5]. Apoptosis 
is the most common programmed cell death pathway in vertebrate organisms and is 
regulated by a number of protein ligands, receptors and proteases. In the extrinsic 
pathway, for example, secreted or membrane-bound Fas ligand (FasLG) binds and 
activates Fas receptor (Fas), which causes formation of a death inducing signaling 
complex (DISC) that recruits and activates caspase 8 [6]. Caspase 8 in turn activates 
several effector caspases including caspase 3 and caspase 7 which ultimately results in 
cell destruction [6]. Thus, modulators of cell survival and proliferation, e.g., inhibitors of 
the extrinsic pathway, whether inherent, or acquired by tumour cells, or even as an 
accidental by-product of medical drug treatment, could ultimately have a serious impact 
on the prevention or promotion of metastatic breast cancer.  
1.1.2.2 Breast cancer metastasis: invasion and migration 
	  
 Metastasis is an incredibly complex multi-step process that requires the ability of 
cells to survive and grow at the primary site, to infiltrate through the resistant barriers of 
surrounding tissue, as well as the ability of cells to migrate in the circulation of newly 
invaded tissues [2-4]. An important role for proteases that can degrade extracellular 
matrices and aid in intra- and extra-vasation has been well documented in these processes 
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[7,8]. For example, recent in vitro observations have identified the mutualistic role of 
metallothioneins (MTs) and metalloproteinases (MMPs) (e.g., MT-2A and MMP-9) in 
promoting cell invasion and migration in breast cancer cells [9]. Thus, modulation of 
mediators of invasion and/or migration, e.g., MT and MMPs, whether intrinsic, or 
acquired by tumour cells, or even as an accidental by-product of medical drug treatment, 
could ultimately have a serious impact on the prevention or promotion of metastatic 
breast cancer. 
1.1.3 Breast cancer subtypes 
 Even within one disease site cancer is not a single disease, but a collection of 
diseases referred to as subtypes. Breast cancer subtypes can be defined very strictly by 
gene expression profiles [10], which yields no less than four breast cancer subtypes: 
luminal, normal breast-like, HER2, and basal-like [10]. Currently, classifying breast 
cancer patient samples at the level of gene expression profiles is proving difficult under 
ideal situations [11,12]. Moreover, in clinical settings it is simply not feasible, although 
steps to overcome existing obstacles are being pursued and developed [13]. Current 
practice, most common in clinics, is the classification of breast cancer samples based on 
the presence or absence of particular steroid hormone receptors: estrogen receptor and 
progesterone receptor. While the receptor status does correlate loosely with molecular 
sub-typing [14], exceptions exist [15]. 
  One of the histological commonalities of the luminal, breast normal-like, HER2, 
and even some basal-like breast cancers is the presence of well-defined molecular targets, 
primarily in the form of the aforementioned protein and hormone receptors [15]. The 
presence of these molecular characteristics provides the basis for targeted treatment and 
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accounts for much of the success in treating these forms of breast cancer. Drugs that 
target the hormone receptors by blocking them, e.g., Tamoxifen [16], or blocking the 
production of  hormones such as estrogen, e.g., Anastrazole, yield much success. 
 Approximately 15% of breast cancers, however, do not express the estrogen or 
progesterone receptor and do not display amplification of the HER2 gene [15]. These 
breast cancers are termed triple negative breast cancers (TNBCs). TNBCs are more 
aggressive, yield shorter survival rates, and higher percentages of relapse in TNBC 
patients [15]. Patients with TNBC have approximately 14% higher distant site recurrence 
rates, and recurrence occurs much quicker, within nearly half the mean number of years 
than other breast cancer subtypes [17]. Thus, metastasis, through invasion and migration 
and subsequent proliferation, occurs more frequently and in shorter time frames for 
TNBC than for other breast cancer subtypes. With over 90% percent of cancer mortality 
resulting from metastasis, inhibition of these aggressive cell behaviour traits is of 
paramount importance [18].  
 Currently, without specific molecular targets, TNBCs cancers are typically treated 
with cocktails of potent cytotoxic chemical therapies [15], including doxorubicin, 
cyclophosphamide, 5-flurouracil, and docetaxel, or a combination of these, to name a 
few. One very commonly prescribed chemotherapy drug is the potent anti-neoplastic 
microtubule poison paclitaxel (Pac). An unfortunate effect of Pac, however, is that it 
frequently causes allergic reactions in patients [19,20]. Moreover, Pac is insoluble in 
water and is dissolved in castor oil, marketed as Kolliphor EL/Cremophor EL, which 
causes hypersensitivity reactions and nausea and vomiting. Pac also causes rashes, 
dyspnea, hypotension, and urticaria [21]. To combat these effects, patients receiving Pac 
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are commonly pre-treated with the anti-inflammatory, anti-emetic synthetic 
glucocorticoid (GC) steroid dexamethasone (Dex) [20,22]. 
1.2 GCs: mechanism of action 
 GCs are lipophilic steroid hormones that regulate a plethora of physiological 
processes involved in defense, metabolism, cell survival and development [23-25]. The 
main GCs produced in mammals are cortisol and corticosterone [24]; cortisol 
predominating in humans [24]. Cortisol is produced in the zona fasciculata of the adrenal 
cortex. Its secretion from the adrenal cortex can be increased beyond basal levels in 
response to adrenocorticotropic hormone (ACTH) from the anterior pituitary. Under 
conditions of stress the anterior pituitary is stimulated to secrete ACTH by corticotropin-
releasing hormone (CRH) from the hypothalamus [24]. The overall hypothalic-pituitary-
adrenal axis is also regulated by a negative feedback loop in which increasing levels of 
blood cortisol inhibits the hypothalamus and/or anterior pituitary from CRH and/or 
ACTH secretion respectively [24]. While cortisol is a lipophilic molecule, most serum 
cortisol is not free to cross cell membranes, as it is bound to a carrier protein 
corticosteroid-binding globulin (CBG) [24]. Also important in GC activation of its target 
receptor is intracellular, pre-receptor metabolism. Inactive GCs (e.g., cortisone in 
humans) are converted to cortisol by 11 beta-hydroxysteroid dehydrogenase (11β-HSD) 
[24] .  
 Reports on the clinical use of cortisol and cortisone as therapeutics for 
inflammatory disease (e.g., rheumatoid arthritis, asthma, etc.) were first presented by Dr. 
Philip Hench and colleagues at the Seventh International Congress on Rheumatic 
Diseases in 1949. For the past 60 years their use has revolutionized the medical field of 
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treating inflammatory disease. GCs are now known to modulate, whether positively or 
negatively, as much as 10% of the human genome [24]. Early clinical use presented 
difficulties however due to the pleiotropic effects of cortisol. In the 1950’s numerous 
groups competed to develop synthetic GCs to minimize unwanted side-effects. Some of 
the synthetic drugs developed during that period continue to be used regularly today; 
some examples include: prednisolone, prednisone, fludrocortisone, methylprednisolone, 
triamcinolone, paramethasone, betamethasone, and Dex [26] . 
 The description of the molecular mechanism of GCs to follow will not focus on 
the particular nuances of each synthetic derivative of cortisol. Rather, a general 
description of GCs mechanisms of action is described. Because the research experiments 
of this dissertation use Dex, any notable distinctions in molecular mechanism of action 
specific to Dex will be identified when and if necessary. Despite the molecular 
mechanism of GCs action being similar from tissue-to-tissue, the target genes and 
pathways affected often vary between tissues. For example, GCs cause programmed cell 
death in many hematopoietic cell lines, but enhance cell survival in solid tissue cell types 
[27]. 
 GCs exert their effect through the cytoplasmic bound nuclear receptor NR3C1 
(nuclear receptor subfamily 3, group C, member 1), also known as: the GC receptor (GR) 
[28]. The GR is held in a stable inactive conformation in the cytoplasm by an inhibitory 
complex of proteins including heat-shock proteins 90, 70 and immunophilins [29]. There 
is also evidence that in certain tissues, the GR interacts with the cytoskeleton when 
inactive [5]. Ligand bound GR can act both genomically (transactivation) and non-
genomically (transrepression) [25]. Genomically the ligand-bound GR homo-dimerizes 
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and translocates to the nucleus where it binds to GC response elements (GREs) in the 
promoter region of its target genes [25]. The GR has also been reported to block access to 
gene promoters, out-competing other transcription factors through DNA binding. Non-
genomically, the active GR can bind other transcription factors through protein-protein 
interaction (e.g., CREB, NFκB, AP-1, STAT-5, etc.), thus blocking their translocation to 
the nucleus and indirectly inhibiting the transcriptional upregulation of their respective 
target genes [25]. 
 Overall Dex is a potent steroid hormone regulating numerous genes involved in a 
plethora of cellular pathways. Dex is commonly used as an anti-emetic in diverse 
chemotherapy settings including, but not limited to, treatment of ovarian cancer [30], 
bladder cancer [22], and colon cancer [31]. Standard clinical protocol regimens list pre-
medication with Dex at a dose of 20 mg given orally 12 and 6 h prior to Pac although 
variance occurs in literature with some prescribing Dex 1 h prior to Pac and other 
multiple times/day leading up to Pac infusion. At the cellular level it is estimated that 
Dex concentration is approximately 1µM and Pac approximately 0.1 µM. With TNBC 
patients receiving Pac, and thus being pre- and co-treated with Dex, it is of clinical 
significance to understand what impact, if any, Dex has on breast cancer cell behaviour 
(Chapter 2 of this dissertation) and response to chemotherapy drugs (the efficacy of Pac 
treatment is addressed in Chapter 3 of this dissertation).   
1.2.1 GCs and cancer cell proliferation 
 Reports concerning the impact of Dex on cancer cell proliferation present an 
unclear picture. Ambiguity on the matter may be due to any one of the three following 
reasons: 1) imprecise use of terminology e.g., conflating “apoptosis” and “cell cycle 
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arrest”. For example, Chung et al [32] cite Frankfurt et al [33] and Goya et al [34] as 
being reports that prove that GCs “inhibit proliferation”, where Frankfurt et al actually 
demonstrated GCs cause apoptosis of hematologic cells and Goya et al demonstrated 
GCs mediate cell cycle arrest in rat mammary cells. While both works demonstrate a role 
for GCs preventing cells from dividing, the mechanisms are very distinct and are only 
loosely related to GCs direct impact on proliferation, as naturally, dead cells do not 
divide. 2) Another cause for lack of certainty regarding the role of Dex in cell 
proliferation is that some reports may actually overreach the extent of the supporting data 
e.g., conflating Dex-mediated protection/cell survival with increases in proliferation. For 
example, a recent report on Dex-mediated increases in proliferation in MCF7 cells was 
supported only by cell viability assays [35]. One concern with this report is the possibility 
that Dex increased the survival of cells allowing them to continue dividing while non-
treated cells slowed or arrested in their division. The point being that, Dex-mediated 
protection from cell cycle arrest is different from Dex-mediated induction of cell 
division. Another example is Zheng et al’s recent working claiming that Dex induces cell 
proliferation in bladder cancer cells [22]. The assay used to make this claim was a cell 
viability assay that measures mitochondrial activity (MTT assay). For the same reason as 
above, these viability assays do not necessarily entail increases in proliferation. Given 
that corroborating data was elusive in the study (i.e., they reported no change in 
proliferation markers, e.g., cyclins or CDK’s) their claims were tempered to a pro-
survival role for Dex although the word ‘proliferation’ was often used interchangeably 
with ‘survival’. Several groups have been very careful to temper their claims on the 
matter of Dex-induced proliferation. Pang et al, for example, observed increases in 
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tumour growth in xenografts of human breast cancer cells in mice. Without corroborating 
data (i.e., they observed no change in Ki-67 levels in Dex treated cells), Pang et al 
suggested that the difference in tumour sizes compared to non-Dex treated cells might be 
attributable to a pro-survival or anti-apoptotic role of Dex rather than a proliferative role. 
3) Confusion may also be due, in part, to the tissue-specific nature of GR regulated genes. 
There is abundant literature showing the pro-apoptotic role of GCs in hematopoietic cells 
[36,37] and so GCs are often described as generally being pro-apoptotic [24]; and yet 
they clearly play an anti-apoptotic role in solid tumour cells [30,31]. There is no 
contradiction here; depending on the cell type, GCs have different effects on cell 
behaviour as pertains to known phenotypes (e.g., effect on apoptosis). Given that the 
ability to elude apoptosis and continue growing at the primary tumour site is a crucial 
characteristic of metastatic breast cancer cells [3], and that breast cancer patients are 
commonly administered Dex it is of clinical significance that the impact of Dex on these 
phenotypes be fully assessed.  
1.2.2 GCs and cancer cell invasion and migration 
 Two other characteristics essential to metastasis of breast cancer cells is their 
propensity to invade and migrate. The subject matter of Dex and cancer cell invasion and 
migration has been reported on in several tissue types. Shiratsuchi et al show that 
activator protein 1 (AP-1) transcriptionally upregulates urokinase-type plasminogen 
activator 1 (uPA) in human squamous cell carcinoma cell lines [38], as part of its 
program to degrade extra-cellular matrix and promote cell motility. AP-1 is a known 
target of active GR transrepression [39] and uPA is also known to be suppressed by Dex, 
not only as demonstrated by Shiratsuchi et al, but also in other tissues [40]. In short, Dex 
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antagonizes an important mediator of invasion in these cells. Other studies pertaining to 
Dex regulation of invasion and migration such as Piette et al’s study in glioma cell lines 
(U373 MG) implicate a role for Dex-mediated inhibition of extracellular signal regulated 
kinase 1/2 (ERK1/2) through transcriptional regulation of dual specificity protein 
phosphatase 1 (DUSP1) [41]. DUSP1 inactivates ERK1/2 by dephosphorylation resulting 
in decreased proliferation, migration and invasion [41]. Zheng et al also report decreases 
in cellular invasion in bladder cancer cells following treatment with Dex [22]. It is of 
clinical significance to determine what impact Dex might have on breast cancer cell 
invasiveness and migratory capacity. If Dex increases these negative characteristics of 
breast cancer then alterations in current clinical protocol are warranted. If, on the other 
hand, as reported in the aforementioned tissue cell lines, Dex inhibits invasion and 
migration, elucidating the mechanisms by which Dex mediates its effects could provide 
better therapeutic strategies. 
1.2.3 GCs and cancer cell survival 
 Although, as mentioned above, GCs (including Dex) are commonly thought of as 
pro-apoptotic [24], there is significant data showing their pro-survival role in solid 
tumour cells [30]. Numerous studies in diverse tissues and organisms support a pro-
survival/anti-apoptotic role for Dex. For example, human and rat hepatocytes [42], 
through B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-XL) signaling, 
are protected from spontaneous apoptosis; human mammary epithelial cells are protected 
from serum withdrawal through upregulation of serum and glucocorticoid kinase 1 
(SGK-1) signaling; and kidney cells are protected from puromycin aminonucleoside-
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induced apoptosis through contrary regulation of Bcl-2 associated X protein (Bax) and 
p53 signaling [43]; all through Dex treatment. 
 Most relevant to the current work, and of clinical significance, is that apart from 
protection against natural stressors and serum withdrawal conditions, increasing data 
demonstrates that Dex can mediate protection against drug-induced apoptosis; in 
particular against chemotherapy-induced apoptosis. Early studies in mice suggested that 
the protective role of Dex could be a beneficial byproduct of using GCs in chemotherapy, 
as Dex was reported to protect bone marrow cells from unwanted cytotoxic effects of 
chemotherapy [44]. In that study, the chemotherapy drug Dex protected against was the 
pyrimidine analog 5-fluorouracil [44]. Huang et al also reported GC mediated protection 
from another group of chemotherapy agents, namely, the Vinca alkaloids vincristine and 
vinblastine [45]. In their study GCs protected breast cancer BCap 37 and epidermoid 
tumour KB cells against Vinca alkaloid induced apoptosis, although the GC used was 
Triamcinalone acetonide (TA) and not Dex specifically [45]. 
 At least two pathways have been identified as playing putative roles in Dex-
mediated rescue from Pac-induced cell death in breast cancer: DUSP1 and IκBα/NFκB 
signaling. Wu et al demonstrated through microarray analysis that early response genes, 
including SGK-1 and DUSP1 were upregulated by treatment with Dex, and that these 
genes could aid in mediating resistance to Pac [46] whether through ectopic expression or 
through their Dex-induced upregulation. Knockdown of these proteins resulted in a 
decrease of Dex’s ability to rescue the cells from Pac-induced apoptosis. Wu et al later 
proposed a pathway in which Dex causes transcriptional upregulation of DUSP1 through 
GR; DUSP1 activity leads to dephosphorylation and inactivation of ERK 1/2 and c-Jun 
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N-terminal kinases 1 and 2 (JNK 1/2) [47]. They observed a correlative decrease in ETS 
domain-containing protein (ELK1) phosphorylation (a downstream target of ERK 1/2 and 
JNK 1/2) [47]. Loss of activation of ELK1 correlated with decreases in Pac-induced 
activation of tissue plasminogen activator (tPA) [47]. Downstream targets of Pac-
activated tPA, however were not elucidated [47]. 
 The IκBα/NFκB signaling pathway has also been identified as a putative 
participant in GC-mediated rescue of ovarian, epidermoid and breast cancer cells from 
Pac-induced apoptosis. Most of the studies examining the role of GC mediated rescue for 
Pac and IκBα/NFκB signaling used the aforementioned synthetic GC TA [48] and not 
Dex, but activation of GR was responsible for the GC-mediated effects nonetheless. Fan 
et al had previously demonstrated that TA could rescue BCap 37, ovarian (OV2008), 
DDT1 MF2 smooth muscle cells, which are a leiomyosarcoma cell line derived from 
hamster ductus deferens, as well as Rat breast cancer cell lines (Con8 and 8RUV7) from 
Pac-induced cell death [49,50]. Moreover, at that time, elucidation of Pac’s diverse 
mechanisms of action was developing. Fan suggested that Pac could induce apoptosis in 
one of three ways: 1) indirectly through activation of mitotic arrest. Microtubule 
stabilization by Pac would cause cells in G2/M arrest to activate cell programmed death 
pathways [51]. 2) Indirectly through microtubule stabilization and apart from mitotic 
arrest; since microtubule dynamic instability is essential for normal functions in a cell, 
Fan proposed that stabilization of microtubules by Pac could activate death pathways 
[51]. 3) Directly though gene regulation; Fan proposed that since GCs do not interfere 
with Pac-induced microtubule stabilization, yet antagonize Pac-induced apoptosis, 
perhaps Dex mediated its effects through inhibition of an essential component of Pac’s 
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program [51]. At the time of Fan’s work, novel reports of NFκB as a potential mediator 
of apoptosis [52,53] were being published. 
  Since NFκB was known to be inhibited by GC/GR signaling, Fan’s group 
assessed what impact Dex might have on Pac-regulation of NFκB signaling. Huang et al 
were able to demonstrate that certain components of the upstream regulatory pathways of 
NFκB were affected by Pac [48,54]. Moreover they were able to demonstrate that the 
most likely point of antagonism between Dex and Pac, as pertains to NFκB signaling was 
in Dex’s ability to transcriptionally upregulate IκBα, the protein inhibitor of NFκB that 
keeps NFκB sequestered in the cytoplasm [48,54]. Further upstream, and unaffected by 
Dex, Pac treatment of BCap37 and OV2008 cells caused increases in mitogen-activated 
protein kinase kinase kinase 1 (MAP3K1) transcripts [48,54]. MAP3K1 causes 
phosphorylation and activation of IKKβ, which Fan showed to cause phosphorylation of 
IκBα. Phosphorylation of IκBα results in its degradation and the subsequent release of 
NFκB for nuclear translocation. These phenotypes were not demonstrated with Dex, nor 
was it reported if these phenotypes held true for other breast cancer cell lines. Moreover, 
the downstream targets for Pac-activated NFκB were not identified, leaving questions as 
to whether or not, and how, NFκB was directly part of the apoptotic program of Pac 
[48,54]. 
1.3 Summary 
 Breast cancer is the most prevalent form of cancer in Canadian women; 
approximately 14 women die each day in Canada from the disease. It is metastasis of 
breast cancer to distant sites that is the leading cause of cancer mortality and not the 
disease at the local primary tumour site. Metastasis of breast cancer, as with other solid 
	  15	  
	  
tumour metastasis, requires several key stages and characteristics of tumour cells: 1) the 
ability of tumour cells to survive (elude apoptosis) and proliferate at the primary tumour 
site; 2) the ability to invade surrounding tissue at primary site; 3) the ability of the cells to 
migrate in circulation or neighbouring tissue and 4) attachment and colonization of 
distant site. Chemotherapy is a potent tool for treating breast cancer. It is primarily used 
for treating the most aggressive breast cancers, namely TNBCs, however it is also used 
for late stage aggressive luminal cancers and luminal cancers that have developed 
resistance to conventional therapies. One of the most commonly used chemotherapy 
drugs is Pac. Because Pac causes hypersensitivity reactions and emetic reactions in 
patients, clinicians administer the synthetic anti-emetic steroid Dex. As a GC, Dex can 
regulate a plethora of genes through activation of GR. These genes are implicated in 
numerous developmental and physiological processes including, but not limited to, cell 
survival, proliferation, invasion and migration. Because Dex is administered in 
chemotherapy regimens, it is of clinical significance to assess what impact, if any, Dex 
treatment might have on cancer cell behaviour. Moreover, it is of clinical significance to 
assess what impact Dex might have on the efficacy of Pac in killing breast cancer cells. 
Elucidating the molecular mechanisms of Dex-mediated protection from Pac could help 
us tailor current clinical regimens and provide insight into Pac-mediated cancer cell 
death, thus providing direction for developing more effective treatments for breast cancer 
patients. 
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Chapter 2: Dexamethasone augments metastatic characteristics of 
breast cancer cells in vitro and in vivo 
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2.1 Introduction 
Breast cancer is a heterogeneous disease that clinicians classify into subtypes 
based on the histological presentation or absence of protein receptors, e.g., estrogen 
receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 
HER2/neu [1,2]. These receptors serve as molecular targets for many conventional anti-
cancer therapies, e.g., Tamoxifen and Trastuzumab. Cancers that present ER and PR are 
generally classified into the luminal subtype, while those lacking these receptors are 
termed basal breast cancers. One subclass of basal breast cancer is termed triple negative 
breast cancer (TNBC) as they lack expression of the ER, PR, and amplification of HER2. 
TNBCs, representing approximately 15% of breast cancers, are one of the most 
aggressive forms of the disease and are among the most difficult to treat as they lack the 
aforementioned molecular targets [3]. To deal with these, clinicians commonly rely on 
cytotoxic drugs such as paclitaxel (Pac) [3]. 
Pac is a microtubule stabilizing agent that causes dividing cells, whether 
cancerous or not, to arrest in metaphase of mitosis [4,5]. Downstream of microtubule 
stabilization, or even through gene regulation independent of microtubule stabilization, 
Pac can cause apoptosis [6-9]. Pac is a very effective chemotherapeutic agent that has 
saved countless cancer patient’s lives over the past twenty years [10]. Unfortunately Pac, 
and in many cases the vehicle in which it is dissolved (Kolliphor EL), causes unwanted 
side-effects. To lessen and even prevent many of these side-effects, glucocorticoids 
(GCs), e.g., dexamethasone (Dex), are administered in advance of chemotherapy [11]. 
Dex mediates its anti-emetic effects through the glucocorticoid receptor (GR). 
Active GR can regulate gene expression of approximately 10% of the human genome 
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[12]. Active GR is involved in the development and regulation of a plethora of 
physiological processes including, but not limited to: inflammation, blood pressure, 
sensitivity to catecholamines, neuronal and glial cell activity, brain, breast, and bone 
development, homeostasis of body temperature, as well as carbohydrate, protein, and 
lipid metabolism [12]. Moreover, GCs can affect the cellular process of division, 
survival, apoptosis, migration and invasion [13-15]; critical processes also implicated in 
metastasis of cancer.  
In general, most breast cancer related deaths are due to metastatic spread of the 
disease and not the primary tumour itself [16]. For metastasis to occur, no less than three 
important cellular characteristics are needed: 1) the ability to survive (elude apoptosis) 
and grow/proliferate at the primary tumour site; 2) the ability to invade through 
boundaries at the primary site, and 3) the ability to move or migrate, whether in 
circulation or within neigbouring tissues [17]. 
 Given that Dex, a potent modulator of cell behaviour, is administered to TNBC 
patients hours, and, in some cases, multiple times per day in advance of chemotherapy, 
we sought to examine what impact Dex might have on breast cancer cell behaviour 
focusing primarily on TNBC cells [18]. Patients with luminal cancers that have 
developed resistance to conventional therapies or present with aggressive forms of the 
disease may also receive Pac, and therefore Dex, hence we also analyzed luminal cancer 
cell behaviour following Dex treatment.  
 We found that GR levels correlated to breast cancer subtypes with TNBCs 
showing the highest expression on average, and the luminal breast cancers showing 
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relatively low expression. We also found that treatment of breast cancers cells with Dex 
increased overall cell numbers, invasiveness, and migratory capacity, compared to non-
treated cells, and that TNBCs demonstrated the most pronounced phenotypes in response 
to Dex. 
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2.2 Material and methods 
Cell culture  
 Human breast cancer cells MCF7 (HTB22; gift from Tiffany Seagroves; 
University of Tennessee: Health Science Center); MDA-MB-231 (HTB26; ATCC), 
Hs578t (HTB126; ATCC), and MDA-MB-468 (HTB132; ATCC) cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM; D5796; Sigma). T47D cells (HTB-133; 
ATCC) were cultured in RPMI-1640 Medium (R8758; Sigma) with 2 units/ml of insulin 
(I-5500; Sigma). SK-BR-3 cells (HTB-30; ATCC) were cultured in McCoy’s 5A 
Medium (30-2007; ATCC). All cells were supplemented with 10% fetal bovine serum 
(FBS; F1051; Sigma) and 1% Penicillin and Streptomycin and were maintained in an 
atmosphere of 5% CO2 at 37˚C. For passaging, seeding, and quantification of cell 
numbers, cells were collected with 0.25% trypsin and counted using the TC10™ 
Automated Cell Counter from BioRad (Catalog #145-0010). Cell media was changed 
from complete media to serum-free media 24-hours prior to treatment. Serum-free media 
was replaced with media containing charcoal-treated FBS (10%) during the treatment 
stage. 
Compounds and antibodies 
 The following antibodies were used at a dilution of 1:1000: Actin (MAB1501R; 
Chemicon) and GR-α (Cat. # 3626-1; Epitomics). Secondary antibodies used were HRP-
conjugated anti-mouse IgG (A9917; Sigma) and anti-rabbit IgG (A0545: Sigma). Charcol 
(C6241; Sigma), Paclitaxel (T7402; Sigma), Dexamethasone (DN1187; BioBasic), and 
RU-486 (Mifepristone; M8056; Sigma). 
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Immuno-blotting 
 Samples were lysed with 0.1% NP40 buffer supplemented with Leupeptin (10 
µg/ml; 103476-89-7; BioBasic), Aprotinin (10 µg/ml; A3428; Sigma), and PMSF (1 mM; 
DB0425; BioBasic). Samples were analyzed by 10% SDS-PAGE and then transferred to 
a PVDF membrane. Primary antibodies were applied and incubated over night at 4°C at 
dilutions specified above. Proteins were detected via treatment with Perkin-Elmer 
Enhanced Chemiluminscence reagent/ECL Western Gel Substrate (NEL10S, Perkin 
Elmer and quantified using FlourChem HD2 software (AlphaInnotech; Perkin Elmer). 
Apoptotic assays 
 Caspase 3/7-glo assay (Promega; G8090) was used to measure the apoptotic state 
of treated cells. 24 h post-treatment cells were collected via trypsinization and lysed. 50 
µl of Caspase-Glo® 3/7 reagent was added in each well of a white-walled 96-well plate 
containing 50 µl of lysis buffer as blank, negative control cell lysates, or treated cell 
lysates with the final concentration of 1 µg/µl. Contents were gently mixed in the wells 
using a plate shaker at 300-500 rpm for 30 sec. Cell lysates were incubated at room 
temperature for 30 min and the luminescence of each sample was measured using Wallac 
Victor 1420 plate reader. 
Migration assay 
 Cells were seeded (1 x 105) in 500 µL of serum-free media in Falcon Cell Culture 
Inserts (353182; Becton-dickinson) in the wells of a 12 well cell culture plate with 1 ml 
of complete media (serum-free control). Cells were treated with ethanol (vehicle control) 
or different concentrations of Dex (0.1 µM, 1 µM, 10 µM, 50 µM, or 100 µM) and 
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incubated for 24 h. Following treatment, the inserts were carefully taken out, cells that 
did not migrate through the pores and therefore remained on the upper side of the filter 
membrane were gently removed, and the migrated cells were quickly stained with 400 µL 
of 1% crystal violet in 2% ethanol for 10 min. The inserts were then merged in water to 
remove excess crystal violet and air-dried. Different views of the cells attached to the 
membrane were imaged using a Leica microscope. The crystal violet was then released 
with extraction buffer and the absorption of the samples was measured at 590 nm using a 
Wallac Victor 1420 plate reader. 
Invasion assay 
 Prior to seeding, cell culture inserts were coated with 100 µl of Cultrex BME 
(3433; Trevigen), diluted to 5 mg/ml, for 4 h at 37°C to gel. Cells were then seeded (1 x 
105) in 500 µL of serum-free media in inserts in the wells of a 12 well cell culture plate 
with 1 ml of complete media (serum-free control). Cells were treated with ethanol 
(vehicle control) or different concentrations of Dex (0.1 µM, 1 µM, 10 µM) and 
incubated for 24 h. Following treatment, the inserts were carefully taken out, cells that 
did not migrate through the pores and therefore remained on the upper side of the filter 
membrane were gently removed, and the migrated cells were quickly stained with 400 µL 
of 1% crystal violet in 2% ethanol for 10 min. The inserts were then merged in water to 
remove excess crystal violet and air-dried. Different views of the cells attached to the 
membrane were imaged using a Leica microscope. The crystal violet was then released 
with extraction buffer and the absorption of the samples was measured at 590 nm using a 
Wallac Victor 1420 plate reader. 
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Animal care and handling 
 Wild-type Zebrafish (Danio rerio) were handled in compliance with local animal 
care regulations and standard protocols of Canada. Adult fish were kept at 28.5°C and 
bred according to protocols available in the Zebrafish Book [19].  
Implantation procedure, treatment, and imaging 
 Zebrafish eggs were collected after fertilization and kept in E3 embryo media (5 
mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4, 10-5% Methylene Blue) at 
28°C in an incubator until ready to inject. Before injection 200,000 cells in 200 µl of 
serum-free media were labeled with 1 µL of DiD (red) (Vybrant; V-22887; Invitrogen) at 
37°C for 20 min. Cells were washed with 200 µl of serum-free media twice and 
resuspended in 20 µl of serum-free media, kept at 37°C for 20 min, and placed on ice 
until ready to inject. 48 h post-fertilization (hpf) the embryos were dechorionated with 
fine tip forceps and anesthetised with 0.168 mg/ml of Tricaine (MS-222; Sigma). 50-100 
labeled cells/9.2 nl were loaded into glass capillary needles and injected into the yolk sac 
of each embryo using a Nanoject II (FSSP9706473; Fisher Scientific). After injection, 
embryos were placed in E3 embryo media and 1 h post-implantation (hpi) were examined 
using a Leica fluorescence stereomicroscope to exclude any embryo with cells outside of 
the implantation area. Following injection, zebrafish were transferred to 96-well plates, 
with one zebrafish per well. Dex was diluted to a final concentration of 1 µM in fish 
water and added to each well of the treatment fish 1 hpi. 24 hpi and 24 h post-treatment 
(hpt) the fish were anesthetized with 0.168 mg/ml Tricaine in a 96-well plate, with one 
embryo per well.  The embryos were imaged using a Leica fluorescence microscope. 
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 All image analysis was completed using ImageJ software and was adapted from a 
previously described method for animal bio-imaging assays [20]. The image sequence for 
each embryo was imported into ImageJ and the image was rotated for each embryo so 
that the injection sites would be aligned. The images were converted to a 32-bit gray-
scale and the threshold was adjusted to eliminate background pixels. The injection sites 
were chosen as the midpoint of the yolk sacs. Using the measure function, the exact 
coordinates for the injection site were measured. The Analyze particle tool was then used 
to record the coordinates of each labeled cell foci within the entire embryo. The 
coordinates of each tumour foci were corrected to the injection site coordinates using the 
formula: (Xfoci-Xorigin,Yorigin-Yfoci). For each focus the distance travelled from the injection 
site was calculated using the formula: √(Xcorrected2+Ycorrected2). The cumulative distance 
(CD) of all foci was calculated per embryo and averaged within an experimental group to 
determine mean CD.  
Statistical analysis 
 Student t test was employed using Statistica software. All results are expressed as 
mean. 
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2.3 Results 
2.3.1 TNBCs express higher levels of GR.  
 TNBC patients are treated with the anti-emetic steroid Dex 1, 6, or 12 h or even 
multiple times per day immediately in advance of, or, in some cases, for days leading up 
to, chemotherapeutic treatment with Pac [21,22]. Dex mediates its effects through the 
GR. We therefore assessed the relative levels of GR across a panel of breast cancer cell 
lines. Three were of the TNBC subtype (MDA-MB-231, Hs578t, MDA-MB-231), and 
three were of the luminal subtype classification (MCF7, SK-BR-3, T47D) (Fig. 2.1). The 
highest levels of expression were presented by the TNBC cells line with the highly 
aggressive MDA-MB-231 cells displaying the highest levels, followed by the Hs578t 
cells and the MDA-MB-468 cells respectively (Fig. 2.1, upper panel). The highest level 
of expression in the luminal cell lines was the MCF7s, with SK-BR-3 and T47D showing 
much lower expression, respectively (Fig. 2.1, upper panel). 
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Figure 2.1 
              
 
Figure 2.1 Relative expression of GR in TNBC and luminal breast cancer cell 
lines. 
TNBC cell lines MDA-MB-231, Hs578t, and MDA-MB-468 and luminal breast cancer 
cell lines MCF7, SK-BR-3 and T47D were lysed and subjected to Western blotting. 
Endogenous GR-α levels were measured by immune-blotting. Densitometry analysis of 
three separate experiments, indicating GR protein levels normalized to Actin, (lower 
panel) is represented as mean ± SEM.  
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2.3.2 Dex increases cell numbers of breast cancer cells in vitro.  
The ability of breast cancer cells to survive at the primary tumour site and to be 
able to grow and proliferate is of critical significance for metastasis [17]. To assess 
whether or not Dex affects the survival and growth of breast cancer cells, we treated 
breast cancer cells representing both TNBC (MDA-MB-231 and Hs578t), and luminal 
subtypes (MCF 7, SK-BR-3, and T47D) with vehicle (control), Dex (1 µM) for 24 h to 
mimic clinical protocol (Fig. 2.2). The two TNBC cell lines, MDA-MB-231 and Hs578t, 
showed the greatest total cell number at 38% and 24% differential between Dex-treated 
and control cells (Figs. 2.2A and 2C). The highest differential between Dex-treated and 
control cells amongst the luminal breast cancer cell lines occurred in MCF7s with 22% 
difference. (Figs. 2.2B and 2C); the MCF7s have the highest GR expression amongst the 
luminal cell lines (Fig. 2.1). The SK-BR-3 and T47D cell lines displayed the smallest 
difference in cell number between treated and control cells at 8% and 7% differential 
respectively (Figs. 2.2B and 2C). These findings correlate with GR protein levels (Fig. 
2.1). 
To assess whether the differential in cell number between Dex-treated and control 
cells was due to proliferative activity or anti-apoptotic activity, we analyzed caspase 3 
and 7 activity under the same conditions using the TNBC cell lines (MDA-MB-468 and 
Hs578t) and the luminal (SK-BR-3 and T47D) cell lines (Figs. 2.2D and 2E). All four 
cell lines showed decreases in caspase 3 and 7 activity indicating that Dex-mediated 
difference in cell number between Dex-treated and control cells may be a result of a Dex-
induced pro-survival and not necessarily increases in proliferation. The cell lines 
expressing the highest levels of GR also demonstrated greater sensitivity to Dex-
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mediated inhibition of the caspases. The Hs578t cells showed 60.7% decrease in caspase 
3 and 7 activity. The luminal cell lines SK-BR-3 and T47D displayed 30.9% and 34.4%, 
respectively. 
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Figure 2.2 
2.2 A. 
 
2.2B. 
              
2.2C. 
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2.2D.                2.2E. 
        
 
Figure 2.2 Impact of Dex on total cell number 24 h post-treatment. 
A. TNBC cell lines MDA-MB-231 and Hs578t and B. luminal breast cancer cell lines 
MCF7, SK-BR-3 and T47D were treated with vehicle (control) or Dex for 24 h. Cells 
were collected and counted for total cell number. C. Graphic representation of the fold-
change in Dex-treated cells relative to vehicle of each respective cell line. D. The TNBC 
cell line Hs578t and E. luminal breast cancer cell lines SK-BR-3, and T47D were treated 
for 24 h with vehicle (control) or Dex for 24 h. Cells were collected and lysed. Luciferase 
activities were measured using equal amounts of cell lysate mixed with Caspase 3/7 Glo 
reagent and luminescence was quantified by spectrophotometry. 
Graphs show the mean value of at least three experiments, each performed in triplicate, 
upon which statistical analysis was performed; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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2.3.3 Dex increases migration of TNBC cell lines in vitro. 
	  	   The migratory properties of a cell are a key parameter in determining metastatic 
capacity. To assess whether Dex could alter the migration of breast cancer cell lines in 
vitro, we performed cyto-select transwell assays. TNBC cells MDA-MB-231s were 
treated with vehicle (control) or a dose range of Dex and cell migration was measured by 
microscopy (Fig. 2.3A; upper panels) and quantified by spectrophotometry (Fig. 2.3A, 
lower panel). A statistically significant increase in migration was observed compared to 
control cells in the MDA-MB-231 cell line. We repeated the migration assay for the 
TNBC cell line MDA-MB-468 with vehicle (control) and with Dex (1 µM). We observed 
a statistically significant increase in migration (Fig. 2.3B). The luminal breast cancer cell 
line T47D did not display an increase in migration following Dex treatment (Fig. 2.3C; 
image not available).  
To ensure that differences in migration of Dex-treated cells compared to control 
cells were not due to Dex-induced proliferation or enhanced survival in the serum-free 
conditions, MDA-MB-231 and MDA-MB-468 cells were seeded in serum-free media on 
tissue culture plates and grown with vehicle (control) or Dex (1 µM) for 24 h (the length 
of the entire migration assay). There was no statistically significant change in cell number 
between treated and control cells in these media conditions (Fig. 2.3D and 3E). Thus, it is 
unlikely that proliferation effects can account for the migration phenotype. To ensure that 
the same would hold true for cells that were in complete media for the duration of the 
assay (i.e., putative cells that migrated immediately after seeding), MDA-MB-231 and 
MDA-MB-468 cells were grown with vehicle (control) or Dex in serum-free media and 
then the media was replaced with complete media for an additional 24 h. No statistically 
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significant change in cell number was observed (Fig. 2.3D and 3E). Thus, it is unlikely 
that Dex-treated cells that migrated had any proliferative advantage over migratory 
control cells once in complete media (as both would be in complete media) during the 
assay timeframe. When MDA-MB-231 cells were left for an additional 24 h (total time in 
complete media = 48 h), a statistically significant difference in cell number was observed 
for Dex-treated cells suggesting a Dex-mediated proliferative or pro-survival advantage 
(Fig. 2.3D). 
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Figure 2.3 
2.3A. 
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2.3B. 
 
 
2.3C. 
           
2.3D. 
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2.3E. 
 
Figure 2.3 Impact of Dex on migration of triple negative and luminal breast 
cancer cell lines in vitro.   
A-C TNBC cell lines MDA-MB-231 (A) or MDA-MB-468 (B) or luminal breast cancer 
cell line T47D (C) were seeded (1x105) in serum-free media in cyto-select migration 
chambers placed in complete media and treated with vehicle (control) or with Dex (dose 
indicated on X axis) for 24 h.  Migration of the crystal violet stained cells through the 
membrane pores was visualized by microscopy (upper panels). Crystal violet-stained 
cells were extracted and quantified by measuring the absorbance at 590 nM (lower 
panels). Scale bars represent 100 µM. D. MDA-MB-231 cells were grown on tissue 
culture plates for 24 h with Dex (1 µM) or vehicle control in serum-free media and 
collected for count of total cell number or media was replaced with complete media for 
an additional 24 h or 48 h. Cells were collected and counted. E. MDA-MB-468 cells were 
grown on tissue culture plates for 24 h with vehicle control or Dex (1 µM) in serum-free 
media and collected for count of total cell number or media was replaced with complete 
media for an additional 24 h. 
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2.3.4 Dex increases invasiveness of TNBC cell lines in vitro.  
 Previous work in bladder cancer cell lines demonstrated that Dex decreased cell 
invasion [14]. To assess the effect of Dex on breast cancer cell lines in vitro, we used a 
cyto-select transwell invasion assay in which the chamber wells were coated with a 
collagen based extra cellular matrix. We treated MDA-MB-231 breast cancer cells with 
vehicle (control) or with increasing concentrations (0.1-10 µM) of Dex. 24 h post-
treatment cells that had migrated through the pores toward complete media were stained 
with crystal violet and imaged (Fig. 2.4A). We observed an increase in invasiveness with 
increases in Dex concentration. Cells were then lysed and analyzed by spectrophotometry 
to accurately quantify invasiveness compared to control (Fig. 2.4A, lower panel). Dex 
caused statistically significant increase in cell number of the highly invasive MDA-MB-
231 (Fig. 2.4B). We also assessed the impact of Dex on invasiveness in Hs578t cells and 
observed statistically significant increases as well (Fig. 2.4C). 
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Figure 2.4 
2.4A. 
 
    
2.4B. 
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Figure 2.4 Dex increases invasiveness of TNBC cell lines in vitro. 
A. MDA-MB-231 and B. Hs578t were seeded in cultrex coated cyto-select migration 
chambers and treated with vehicle (control) or with Dex (at the indicated concentration 
for 24 h). Cells were stained with crystal violet and images were taken with Leica 
microscope (upper panels). Crystal violet-stained cells were extracted and quantified by 
spectrophotometry at absorbance of 590 nM (lower panels). The absorption data from 
which they were averaged are presented as the means ± SEM. *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001. 
 
 
 
 
 
 
 
 
	  
 
	  
	  
	  45	  
	  
2.3.5 Dex increases metastatic properties of TNBC cell lines in vivo. 
To examine the effect of Dex on breast cancer cell behaviour in vivo DiD labeled 
MDA-MB-231 cells were injected into the yolk sack of zebrafish. Zebrafish were grown 
in water with and without Dex. 24 h post treatment (hpt) the fish were anesthetized and 
imaged using a Leica fluorescence microscope. 
  As expected of the highly aggressive MDA-MB-231 cells, numerous cells were 
found re-localized in the tail vein of the control zebrafish. The addition of Dex to the fish 
water, however, resulted in a statistically significant increase in the number of re-
localized cells compared to controls (Fig.3.5J). Moreover, the average cumulative 
distance (measured in µm) traveled by the Dex-treated fish was statistically significant 
compared to control fish (Fig. 3.5K) 
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Figure 2.5 
 
2.5I. 
 
2.5J. 
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2.5K. 
 
 
Figure 2.5 Dex augments metastatic characteristics of TNBC cells in zebrafish 
model.  
A. Cells were labeled with a fluorescent marker and implanted into 48 h post-fertilization 
(hpf) embryos. B. Embryos were treated in a 96-well plate with Dex 1 h post-injection 
(hpi). C. Embryos were anesthetized and imaged with a fluorescent microscope 24 h 
post-treatment. D. Multiple Z plane images were taken of each embryo and E. composite 
images were made using ImageJ software. F. All composite images were gathered, G. 
aligned to a specific orientation, and H. analyzed to determine tumour foci position 
relative to injection site (0.0 of graph).  Each data series represents one fish. Axes 
represent the distance (µm) from the injection site. (I) Representative brightfield and 
fluorescent images taken 24 hpi of MDA-MB-231 cells injected into 48 hpf embryos and 
treated with or without Dex from 1 hpi to 24 hpi. J. Graphs of tumour coordinate 24 hpi 
and 24 h post treatment. K. Graph of cumulative distance (CD) from injection site for 
tumour foci. Each point represents CD of one embryo and line represents mean CD. 
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2.4 Discussion 
 30% of breast cancer patients develop metastatic breast cancer for which there is 
no cure [23]. Metastatic breast cancer cells present several key characteristic, namely 1) 
the ability to survive by eluding apoptosis and continuing to grow and proliferate at the 
primary tumour site; 2) the ability to invade through surrounding tissue; 3) the ability to 
migrate in circulation or within neighbouring tissues and 4) colonization at distant sites 
[23,24]. These characteristics may be intrinsic or acquired through mutation [24]. 
Alternatively these characteristics could potentially be augmented by drug treatment.  
Thus, the effect of clinical therapies and adjuvant drugs on breast cancer cell 
characteristics is of clinical significance to progression of metastasis. 
In chemotherapy regimens, Pac is administered to TNBC patients and luminal 
breast cancer patients with late stage, aggressive breast cancer and those that display 
resistance to conventional therapies. Pac, despite being a very effective chemotherapy, 
causes allergic and hypersensitivity reactions as well as nausea and vomiting in patients 
[4,25]. Dex is administered to breast cancer patients in advance and along with Pac to 
combat these effects [25,26].  
 We demonstrate that administration of Dex increases cell number, migratory 
capacity and invasiveness within 24 h post-treatment relative to vehicle-treated control 
cells in vitro (Figs. 2.2-2.4). Previous reports claim that Dex increases cell proliferation 
in solid cancer cells [14,15]. These previous studies used only cell viability assays and no 
counts were performed. While we did perform cell counts, neither our data, nor those 
reports, excludes the possibility that differences in Dex-treated cell number versus control 
cell number are due to increased survival and not increased proliferation. At most we 
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show that Dex allowed cells to continue dividing better than those that did not receive 
Dex (Fig. 2.2A and 2B). Thus, differences in cell number compared to control could be 
attributable to enhanced cell survival with Dex. Zheng et al also report that their claims 
of increased proliferation were not corroborated by increases in the proliferative markers, 
cyclins and CDKs [14]. Pang et al also interpret data concerning Dex-mediated increases 
in tumour size that did not show increased expression of Ki-67 as most likely being due 
to an increase in survival [27]. Furthermore, and consistent with these findings, we 
demonstrate that Dex decreased activity of caspases 3 and 7 compared to control cells 
(Fig. 2.2D and 2E). These differences in caspase activity may account for variance in the 
cell number of Dex-treated cells compared to control populations. Further analysis with 
BrdU incorporation or Ki-67 expression could give insight into this matter of concern. 
 We also demonstrate that Dex-treated breast cancer cells have increased motility 
as evident in migration and invasion assays (Figs. 2.3 and 2.4). One alternate explanation 
to our data that must be considered however is that the Dex-treated cells were surviving 
and/or proliferating faster producing more cells on the pre-migration and pre-invasion 
side of the chambers compared to control chambers. Thus, even if equal percentages of 
cells migrated or invaded thereafter, the Dex-treated chambers would have more cells to 
migrate or invade and a selective advantage over control chambers. Another alternative 
explanation to our observation is that while Dex would confer no advantage in cell 
number pre-migration or pre-invasion, Dex treated cells would be ‘primed’ for increased 
proliferation or survival compared to control cells once they reached the complete media 
post-migration or post-invasion. In this model equal numbers of cells exist in both the 
control and Dex-treated cell chambers pre-migration or pre-invasion and equal numbers 
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of cells migrate or invade. Once these cells reach complete media, however, the Dex 
treated cells proliferate sooner and thus account for differences in the assay. We 
demonstrate that neither of these explanations can account for the observed data in the 
conditions and brief timeframe that the experiment takes place (Figs. 2.3D and 3E). 
Given longer periods of time, however, we show that the latter explanation could be true 
and further supports our earlier report that Dex enhances survival and/or proliferation in 
breast cancer cells (Fig. 2.3D). 
 Our in vivo data supports Dex’s role in enhancing one, if not more, characteristics 
of metastatic breast cancer cells. Which of the Dex-mediated effects i.e., 
proliferation/survival, migration or invasion is most essential for this phenotype is 
currently unknown (Fig. 2.5). Given that Dex affects proliferation/survival of the MDA-
MB-231 breast cancer cells it is possible that cells proliferate more in the yolk sack and 
hence more cells were present to invade and migrate to distant sites, properties MDA-
MB-231 cells possess intrinsically. Also, it may be that these highly invasive cells exited 
the yolk sack with equal efficiency compared to non-treated fish, but Dex mediates 
proliferation or survival of invasive cells thus affecting total cell number at the time of 
quantification. Consistent with this explanation, Zheng et al ascribed increases in tumour 
mass in mice xenografts of Dex treated mice to increased survival of tumour cells 
resulting in larger tumours [14]. Another possibility is that Dex increased the invasive 
properties or the migratory properties but had no impact of survival or proliferation in the 
fish. This explanation would conflict with Zheng et al’s report that no invasion or 
migration happened in xenografts of bladder cancer cells in Dex-treated mice [14]. It 
would also conflict with several groups’ in vitro and in vivo work. A search of the 
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literature shows several reports on Dex as reducing migration and invasion [13,14,28,29]. 
These studies are not in breast cancer cell lines and most are in vitro. For example, 
Hayashido et al report that Dex causes down-regulation of uPA and increases in 
plasminogen activator inhibitor type 1 (PAI-1) resulting in decreased invasion through 
collagen type 1 gel in squamous cell carcinoma [13]. Shiratsuchi et al also show Dex 
decreases invasion in squamous cell carcinoma through inhibition of uPA signaling, 
effectively blocking epidermal growth factor-induced invasion [29]. In vitro and in vivo 
work by Zheng et al show that Dex down-regulates expression of invasion-related genes 
(MMP-2/MMP-9, IL-6, VEGF) and also reduced the development of bloody ascites in 
xenograft mice, an indicator of metastasis [14]. GR activity is tissue specific and further 
research into the mechanisms by which Dex causes increases in migration and invasion 
may provide insight into the differences compared to these aforementioned studies. 
In conclusion, Dex impacts breast cancer cell behaviour as pertains to 
survival/proliferation, invasion and migratory capacity. Given the common usage of Dex 
in treating breast cancer patients with the most severe forms of breast cancer further 
research into elucidating the molecular mechanisms driving these effects and the impact 
of Dex on overall breast cancer outcomes is warranted. 
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Chapter 3: Paclitaxel-induced transcriptional regulation of Fas 
signaling pathway is antagonized by dexamethasone 
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3.1 Introduction 
Glucocorticoids (GCs) regulate numerous physiological parameters and are 
involved in the development and maintenance of many tissues [1-3]. GCs can act both 
genomically and non-genomically. Genomically, GCs activate the glucocorticoid receptor 
(GR) which translocates to the nucleus where, upon binding DNA, it can activate or 
repress the expression of hundreds of genes [2]. The genomic effect of active GR is also 
tissue specific [2]. GCs can activate apoptosis in hematopoietic cells [2,4,5], yet they 
have been shown to inhibit apoptosis in solid tumour cells [6]. While the sensitivity of 
hematopoietic cells to GCs serves as the basis of synthetic GC use in treatment of 
leukemias [5,7], the protective role of GCs in solid tumours has been reported in ovarian, 
epidermoid, muscle, and breast cancer cells [6,8,9]. The clinical significance of the 
pleiotropic and tissue-specific impact of GCs is that beyond their use as part of the 
chemotherapy proper in leukemias, synthetic GCs (e.g., dexamethasone (Dex)) are also 
administered to breast cancer patients as antimetics. As such, Dex efficiently reduces 
nausea and vomiting as well as suppresses hypersensitivity reactions induced by 
chemotherapy drugs (e.g., paclitaxel (Pac)) and the vehicles in which they are delivered 
(e.g., Koliphor EL). Disconcerting is the growing body of data warning of the protective 
role of GCs in solid tumours [8,10-12]. Despite such evidence, to date there have been no 
clinical trials examining the effect of Dex on tumour response or the efficacy of Pac [6]. 
Pac is a microtubule-stabilizing agent that causes metaphase arrest in mitotic cells 
[13]. Pac also activates cell death programs both downstream of microtubule stabilization 
as well as independent of microtubule stabilizing effects [14]. Previous reports have 
identified Pac-activated mediators of apoptosis, which happen to also be contrarily 
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regulated by Dex (e.g., SGK-1, DUSP-1, IκBα) [6,15-18]. The mechanisms by which Pac 
modulates these pathways have been partially elucidated, but there remains much to be 
explained; especially as pertains to the putative targets of these pathways. For example, 
Huang et al reported on regulation of the transcription factor NFκB through IκBα 
degradation, and activation of other upstream regulators of NFκB, as a mediator of Pac-
induced apoptosis in human breast BCap37, human ovarian OV2008, and human 
epidermoid tumour KB cells [18]. Nevertheless, the specific downstream targets of Pac-
activated NFκB and how these might regulate Pac-induced apoptosis remains unclear. 
In clinical practice, breast cancers are often identified histologically based on the 
presence, absence, or levels of particular receptors that serve as markers for targeted 
therapy (e.g., estrogen, progesterone, or HER2). Tumours that present with the estrogen 
receptor (often termed luminal), for example, can be treated with Tamoxifen or other 
estrogen antagonists. Breast cancers that do not express the estrogen or progesterone 
receptor, or do not display amplification of HER2 are termed triple-negative breast 
cancers (TNBCs) and are very aggressive with low overall survival rates [19]. These 
cancers are treated with potent cytotoxic drugs (e.g., Pac). Pac may also be used on non-
TNBCs that are late stage aggressive luminal breast cancers and/or other luminal breast 
cancers that have become resistant to traditional therapies. Because Pac serves as a last 
line of defense against the most aggressive forms of breast cancer, ensuring optimal 
conditions of efficacy is of paramount therapeutic importance. Elucidating the molecular 
pathways of Dex-mediated protection against Pac will not only help us better understand 
how Pac kills cancer cells, but might provide insight into sensitizing breast cancers to 
chemotherapy by identification of putative targets.  
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In clinical settings Dex is administered at least one hour prior to Pac. We show 
that both TNBCs and luminal breast cancers respond to Pac, and that Dex rescues these 
cells from Pac-induced apoptosis (most significantly in TNBCs). We show in several of 
the most Pac-sensitive cell lines that Pac activates NFκB. Furthermore, we show that 
NFκB is an important mediator of Pac-induced apoptosis and a target of Dex-mediated 
rescue from Pac-induced apoptosis. We then searched for potential NFκB-regulated 
transcripts. We report here that both Fas ligand (FASLG) and Fas receptor (FAS) are 
upregulated by Pac.  These transcripts are contrarily regulated by Dex and Pac-induced 
transcriptional regulation of Fas is antagonized by Dex. We present a critical component 
of the protective role of Dex in Pac-mediated apoptosis. 
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3.2 Materials and methods  
Cell culture  
 Human breast cancer cells MCF7 (HTB22; gift from Tiffany Seagroves; 
University of Tennessee: Health Science Center); MDA-MB-231 (HTB26; ATCC), 
Hs578t (HTB126; ATCC), and MDA-MB-468 (HTB132; ATCC) cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM; D5796; Sigma). T47D cells (HTB-133; 
ATCC) were cultured in RPMI-1640 Medium (R8758; Sigma) with 2 units/ml of insulin 
(I-5500; Sigma). SK-BR-3 cells (HTB-30; ATCC) were cultured in McCoy’s 5A 
Medium (30-2007; ATCC). All cells were supplemented with 10% fetal bovine serum 
(FBS; F1051; Sigma) and 1% Penicillin and Streptomycin and were maintained in an 
atmosphere of 5% CO2 at 37˚C. For passaging, seeding, and quantification of cell 
numbers, cells were collected with 0.25% trypsin and counted using the TC10™ 
Automated Cell Counter from BioRad (Catalog #145-0010). Cell media was changed 
from complete media to serum-free media 24-hours prior to treatment. Serum-free media 
was replaced with media containing charcoal-treated FBS (10%) during the treatment 
stage. 
Plasmids 
 3X-MHC-luc NFκB plasmid was a generous gift from Christine Pratt (Ottawa). 
The sh Scramble-pLKO.1-puro was constructed by using the scrambled sequence; 
CCTAAGGTTAAGTCGCCCTCG. The gene-specific shRNA expression plasmids were 
constructed using synthetic oligonucleotides targeting NFκB1, 
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GATGACATCCAGATTCGATTT, and RELA, CCTGAGGCTATAACTCGCCTA, 
which were cloned in the pLKO.1-puro plasmid (8453; Addgene). 
Transfection  
 Cells were transiently transfected using jetPRIME (CA89129-922; VWR). Total 
of 3 µg plasmid DNA was diluted into 200 µl jetPRIME buffer. After vortexing the mix, 
4 µl jetPRIME was added and vortexed. Reaction was incubated for 10 min at room 
temperature. The transfection mix was added drop-wise into the medium. Cells were 
incubated at 37˚C for at least 24 h.  
Infection 
 MDA-MB-468 cells were infected with virus:culture media ratio of 1:1, 
supplemented with 8 µg/ml polybrene and incubated for 8 h. Cells were then recovered 
for 24 h in their relevant culture media prior to addition of puromycin (1 µg per ml of 
media) for stable cell line generation. 10 days after selection, colonies were picked for 
expansion and screening for expression.   
Compounds and antibodies  
 The following antibodies were used at a dilution of 1:1000 dilution: Actin 
(MAB1501R; Chemicon), p105/p50 (1559; Epitomics), p65 (1546; Epitomics), and Fas 
(5709-1; Epitomics). Secondary antibodies used were HRP-conjugated anti-mouse IgG 
(A9917; Sigma) and anti-rabbit IgG (A0545: Sigma). Charcoal (C6241; Sigma), 
Paclitaxel (T7402; Sigma), Dexamethasone (DN1187; BioBasic), and RU-486 
(Mifepristone; M8056; Sigma). 
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Immuno-blotting 
 Samples were lysed with 0.1% NP40 buffer supplemented with Leupeptin (10 
µg/ml; 103476-89-7; BioBasic), Aprotinin (10 µg/ml; A3428; Sigma), and PMSF (1 mM; 
DB0425; BioBasic). Samples were analyzed by 10% SDS-PAGE and then transferred to 
a PVDF membrane. Primary antibodies were applied and incubated over night at 4°C at 
dilutions specified above. Proteins were detected via treatment with Perkin-Elmer 
Enhanced Chemiluminscence reagent/ECL Western Gel Substrate (NEL10S, Perkin 
Elmer and quantified using FlourChem HD2 software (AlphaInnotech; Perkin Elmer).  
Luciferase assays 
 Cells were harvested 24 h post-transfection with luciferase constructs and mixed 
with Bright-glo reagent (E2610; Promega), at 1:1 ratio. Luminescence spectra of the 
samples were measured using a Wallac Victor 1420 plate reader (PerkinElmer 3TM-
1420). 
Apoptotic assays 
 Caspase 3/7-glo assay (Promega; G8090) was used to measure the apoptotic state 
of treated cells. 24 h post-treatment cells were collected via trypsinization and lysed. 50 
µl of Caspase-Glo® 3/7 reagent was added in each well of a white-walled 96-well plate 
containing 50 µl of lysis buffer as blank, negative control cell lysates, or treated cell 
lysates with the final concentration of 1 µg/µl. Contents were gently mixed in the wells 
using a plate shaker at 300-500 rpm for 30 sec. Cell lysates were incubated at room 
temperature for 30 min and the luminescence of each sample was measured using Wallac 
Victor 1420 plate reader. 
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qRT-PCR analysis 
 24 h post-treatment, cells were collected via trypsinization and total cell RNA was 
extracted using RNeasy Plus Mini Kit (Qiagen; 74134). RNA was converted to first 
strand cDNA using SuperScriptTM II Reverse Transcriptase (18064; Invitrogen). Relative 
quantities of mRNA expression were quantified using the following oliogs: 5'-
CCCATTTAACAGGCAAGTCCAA-3' and 5'-
AAGTACAGCCCAGTTTCATTGATCA-3' for FASLG and 5'-
ATCTAACTTGGGGTGGCTTTGTC-3' and 5'-
ATTTATTGCCACTGTTTCAGGATTT-3' for FAS and analyzed using ViiA 7 software 
1.1 (ABI Viia7 Real Time PCR System). Cells were collected following respective 
treatment and their total RNA was subjected to real time PCR. Expression levels were 
normalized to GAPDH and presented as fold relative to the control. 
 Statistical analysis 
 Student t test was employed using Statistica software. All results are expressed as 
mean ± SEM and differences were considered significant at p values of <0.05. 
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3.3 Results 
3.3.1 Both ER+ luminal and TNBC cells are sensitive to Pac in vitro.  
Pac treatment is reserved primarily for patients with TNBC in clinical settings. 
Patients with luminal breast cancers may also receive Pac if late diagnosis shows an 
aggressive phenotype or if the patient exhibits resistance to more conventional therapies. 
To assess the sensitivity of breast cancer cells to Pac we treated six breast cancer cell 
lines, representing both luminal and TNBC subtypes of breast cancer (luminal: MCF 7, 
SK-BR-3, T47D; TNBC: Hs578t, MDA-MB-231, MDA-MB-468), with Pac (0.1 µM). 
Cells were then collected and counted via trypan blue exclusion. Each cell line showed 
statistically significant reduction in total viable cell number (Fig. 3.1). The TNBCs 
showed, on average, the greatest statistically significant reduction in viable cell numbers 
to Pac (Fig. 3.1A) when compared to the luminal breast cancers (Fig. 3.1B). The most 
sensitive cell lines, as measured by percentage of decrease in viable cell number, were the 
MDA-MB-468 (64% decrease), and Hs578t cell lines (62.8% decrease) (Fig. 3.1C).  
 
 
 
 
 
 
 
 
	  65	  
	  
Figure 3.1  
3.1A. 
 
3.1B. 
              
3.1C. 
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Figure 3.1 TNBC and luminal breast cancer cell line sensitivity to Pac. 
A. TNBC cell lines MDA-MB-468, Hs578t, and MDA-MB-231 cells were treated for 24 
h with vehicle (NT) or Pac and collected for cell count of total live cell number. B. 
Luminal breast cancer cell lines MCF7, SK-BR-3 and T47D cells were treated with Pac 
or NT for 24 h and collected for cell count of total live cells. C. Percentage of decrease in 
average of total cell numbers of Pac treated breast cancer cells compared to average 
number of vehicle-treated control numbers. 
All the experiments were performed at least three times and represented as mean ± SEM. 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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3.3.2 Dex treatment enhances cell survival in Pac-treated breast cancer through 
inhibition of Pac-induced apoptosis. 
 In the clinic, breast cancer patients receive Dex at least 1 h prior to receiving Pac; 
we similarly treated six breast cancer cell lines (two representatives of TNBCs and three 
of luminals) to assess the impact of Dex pre-treatment on the efficacy of Pac. For the 
three TNBC cell lines pre-treatment with Dex produced statistically very significant 
rescue of total viable cell number (Figs. 3.2A and 2C). For the three luminal cell lines, 
the results were mixed (Fig. 3.2B). The rescue effect of Dex was most significant for the 
MCF-7 cells (Fig. 3.2B, left panel), which were also the most Pac sensitive of the luminal 
cell lines (Fig. 3.1C). The SK-BR-3 and T47D luminal cell lines displayed no statistically 
significant rescue in total cell number with Dex (Fig. 3.2B, bottom panels). To ensure 
that the Dex-mediated rescue was downstream of GR activation we treated MDA-MB-
468 cells with the GR antagonist Mifepristone (RU-486) (Fig. 3.2C). GR inhibition by 
RU-486 completely mitigated any Dex-mediated rescue from Pac (Fig. 3.2C). 
 To further assess the means by which Dex mediates its protection from Pac, we 
performed an apoptotic assay examining caspase 3 and 7 activity in the two most Pac-
sensitive, MDA-MB-468 and Hs578t, and least Pac-sensitive, SK-BR-3 and T47D, cell 
lines (Fig. 3.2D). In all four cell lines, pre-treatment with Dex 1 h in advance of Pac 
yielded statistically very high rescue from Pac-induced apoptosis (Fig. 3.2D). 
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Figure 3.2 
3.2A. 
                 
3.2B. 
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3.2C. 
 
3.2D. 
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Figure 3.2 Pro-survival and anti-apoptotic role of Dex from Pac in TNBC and 
luminal breast cancer cell lines. 
A. and B.  TNBC cell lines, MDA-MB-231 and Hs578t, and luminal breast cancer cell 
lines, MCF7, SK-BR-3, and T47D were treated for 24 h with vehicle (NT), Dex, Pac, or 
co-treated with Dex and Pac (Dex 1 h prior to Pac). Cells were then counted for total cell 
number. C. MDA-MB-468 cells were treated for 24 h with vehicle, Dex, Pac, or co-
treated with Dex and Pac (Dex 1 h prior to Pac) with or without RU-486. Cells were then 
counted for total cell number. D. TNBC cell lines MDA-MB-231 and Hs578t (upper 
panels) and luminal breast cancer cell lines SK-BR-3 and T47D (lower panels) were 
treated for 24 h with vehicle, Dex, Pac, or a combination of Dex and Pac (Dex 1 h prior 
to Pac). Cells were collected and lysed. Luciferase activity was measured using equal 
amounts of cell lysate mixed with Caspase 3/7 Glo buffer and luminescence was 
measured by spectrophotometry. 
Graphs show the mean value of at least three experiments, each performed in triplicate, 
upon which statistical analysis was performed; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
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3.3.3 Contrary regulation of NFκB by Pac and Dex.  
 Previous reports demonstrated that upstream regulators of NFκB signaling were 
affected upon Pac-treatment [17,18]. GCs, including Dex, are potent inhibitors of NFκB 
inflammatory signaling, hence we sought to determine if NFκB was an important 
mediator of Pac-induced apoptosis in these cell lines, and if Dex-mediated rescue of Pac-
treated breast cancer cells was caused by inhibition of NFκB. To determine if Dex-
mediated rescue from Pac-induced apoptosis is via NFκB, a construct bearing three 
copies of the promoter for the major histocompatibility complex class 1 ((MHC-1), a 
known transcriptional target of NFκB) upstream of a gene for luciferase was transiently 
transfected into MDA-MB-468 cells. 24 h following transfection, cells were treated with 
or without Pac and collected at 8, 12, and 24 h (Fig. 3.3A). Cell lysates were analyzed by 
spectrophotometry for overall luminescence. Pac-treated cells showed statistically 
significant increases in luciferase activity at all three time points demonstrating increased 
Pac-induced activation of the NFκB transcription factor (Fig. 3.3A).  To assess the impact 
of Dex-treatment and co-treatment of Dex and Pac, MDA-MB-468 and MDA-MB-231 
cells were transiently transfected with the same construct as above. Cells were treated for 
24 h with either vehicle (NT), with Dex, Pac, or with co-treatment of Dex and Pac (Dex 1 
h prior to Pac). Cells were then collected and lysates were measured for overall 
luminescence (Fig. 3.3B). For both MDA-MB-468 and MDA-MB-231 cells, Pac 
increased luminescence indicating an enhanced activation of NFκB. Importantly, 1 h pre-
treatment with Dex completely antagonized Pac-induced NFκB activity (Fig. 3.3B). 
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Figure 3.3 
3.3A. 
 
3.3B. 
      
Figure 3.3 Pac upregulates activity of NFκB and is antagonized by Dex. 
A. MDA-MB-468 cells were transiently transfected with 3X-MHC-luc NFκB reporter 
construct. Cells were then treated with the vehicle or Pac for 8, 12, and 24 h, and 
collected and lysed. Cell lysates were mixed with Bright-glo assay buffer and 
luminescence was measured by spectrophotometry. B. MDA-MB-468 and MDA-MB-
231 cells were transiently transfected with 3X-MHC-luc NFκB reporter construct for 24 
h. Cells were then treated with vehicle (NT), Dex, Pac, or co-treated with Dex and Pac 
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(Dex 1 h prior to Pac) for an additional 24 h, collected and lysed. Cell lysates were mixed 
with Bright-glo assay buffer and luminescence was measured by spectrophotometry. 
Represented data are mean ± SEM of three individual experiments, each performed in 
triplicate. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.  
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3.3.4 Knock-down of NFκB subunits desensitizes breast cancer cells to Pac and 
diminishes Dex-mediated rescue from Pac.  
 NFκB1 transcript produces p105, which is then cleaved to p50 before binding to 
the RELA gene product p65 to form the canonical NFκB transcription factor complex. To 
assess the essentiality of NFκB as a mediator of both Pac-induced apoptosis and Dex-
mediated rescue from Pac, we knocked down both NFκB1 (p50) and RELA (p65) 
subunits of NFκB through lentiviral infection of shRNA constructs. Successful knock-
down of NFκB1 was observed in stably infected MDA-MB-468 cells displaying nearly 
90% decrease in p50 protein levels (Fig. 4A). Interestingly, knock-down of NFκB1 
resulted in significant decrease of p65 protein as well (Fig. 3.4A; left panel). Control and 
NFκB1 knock-down cells were treated for 24 h with vehicle (NT), Dex, Pac, as well as 
co-treatment with Dex and Pac (Dex 1 h prior to Pac), and total cell number of each 
sample was assessed (Fig. 3.4A; right panel). Knock-down of NFκB1 significantly 
reduced Pac-mediated apoptosis showing only a 6.21% decrease (p=0.0487) in viable cell 
number compared to over a 50% reduction (p=0.0021) in control cells. Dex rescued over 
40% (p=0.001) of control cells, while the rescue was completely lost in the NFκB1 
knock-down cells. 
  Just as for NFκB, stably infected MDA-MB-468 cells were generated for knock-
down of RELA. The knock-down of RELA proved highly successful resulting in 87.9% 
decrease of p65 levels (Fig. 3.4B; left panel). MDA-MB-468 cells infected with sh 
Scramble or sh RELA were treated for 24 h with vehicle or with Dex, Pac, or Dex plus 
Pac (Dex 1 h prior to Pac), and total cell number for each sample was assessed (Fig. 
3.4B; right panel). Unlike cells depleted of p50 protein, knock-down of RELA did not 
	  75	  
	  
alter the ability of Pac to decrease cell number as much as knockdown of p50 did. 
Importantly, as seen in NFκB1 knock-down cells, knock-down of RELA abrogated Dex-
induced protection, showing only a slight decrease in total cell number of 8% compared 
to Pac only cells (Fig. 3.4B; right panel). NFκB appears to play an important role in both 
Pac-induced decrease in viable cells and Dex-mediated rescue of cells from Pac. The 
most notable changes in cellular response to Pac and Dex were observed in the sh NFκB1 
cell line, which may be attributed to the significant decrease in both subunits being 
knocked down (Fig. 3.4A). To assess the impact of knock-down of NFκB1 and RELA on 
Pac-induced apoptosis and Dex-mediated rescue for Pac we performed an apoptotic assay 
examining caspase 3 and 7 activity levels (Fig. 3.4C). Both sh NFκB1 and sh RELA cell 
lines showed statistically significant decrease in sensitivity to Pac-induced apoptosis. 
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Figure 3.4  
3.4A. 
          
3.4B. 
           
3.4C. 
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Figure 3.4 Essentiality of NFκB for Pac sensitivity and Dex-mediated rescue of 
breast cancer cells. 
A. MDA-MB-468 cells were stably infected with sh Scramble control or sh NFκB1 
construct, and lysates were subjected to immuno-blotting to monitor for p50 and p65 
protein levels (left panel). The membrane was probed for p105/p50, p65 and Actin as a 
loading control. The stable cells were also treated for 24 h with vehicle (NT), Dex, Pac, 
or co-treated with Dex and Pac (Dex 1 h prior to Pac). Cells were then collected and 
counted for total cell number (right panel). B. Lysates from MDA-MB-468 cells stably 
infected with a sh Scramble, as the control, or sh RELA were subjected to immuno-
blotting to monitor for p105/p50 and p65 protein levels (left panel). The same membrane 
was used to probe for Actin to ensure equal protein loading. Percentage of knock-down 
was calculated by densitometry. The stable lines were also treated for 24 h with vehicle 
(NT), Dex, Pac, or co-treated with Dex and Pac (Dex 1 h prior to Pac). Cells were then 
collected and counted for total cell number (right panel).  C. Stable sh Scramble, sh 
NFκB1, and sh RELA cells were treated with vehicle (NT) or with Pac for 24 h. Cells 
were collected and lysed. Luciferase activities of the lysates were measured using equal 
amounts of cell lysate mixed with Caspase 3/7 Glo buffer and luminescence was 
measured by spectrophotometry. 
Bars indicate SEM of at least three individual experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 
0.001. 
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3.3.5 Contrary transcriptional regulation of FASLG and FAS by Pac and Dex. 
 NFκB regulates more than one hundred and fifty genes. Previous reports in T 
lymphocytes identified binding sites for NFκB in the promoters of pro-apoptotic FASLG 
and FAS, which are the genes for the Fas ligand and Fas receptor respectfully [20,21]. To 
search out a putative target of Pac-activated NFκB and mechanism by which Dex 
antagonizes Pac we analyzed changes in FASLG mRNA levels 24 h post-treatment with 
vehicle (NT), or with Dex, or Pac, or with co-treatment with Dex and Pac (Dex 1 h prior 
to Pac) for MDA-MB-468, Hs578t and MDA-MB-231 cells (Fig. 3.5A). Pac increased 
transcriptional expression of FASLG in all three cell lines. And, while Dex alone showed 
decreases in FASLG expression levels for all three cell lines, it was not able to decrease 
Pac-induced FASLG expression to any statistically significant degree (MDA-MB-468 
(p=0.8948), Hs578t (p=0.9504), MDA-MB-231 (p=0.1013)). We repeated the experiment 
analyzing changes in mRNA for FAS (Fig. 3.5B). For all three cell lines Pac-induced 
increases in FAS expression, and Dex-treated cells displayed an overall decrease in FAS 
expression. Unlike for FASLG, however, pre-treatment with Dex was able to override 
Pac-induced FAS expression in a statistically significant manner (MDA-MB-468 
(p=0.0170), Hs578t (p =0.0075), MDA-MB-231 (p=0.02)) (Fig. 5B). To assess potential 
changes in Fas receptor protein with and without Dex, Pac, and Dex plus Pac (Dex 1 h 
prior to Pac) for Hs578t western blot analysis was conducted (Fig. 3.5C). The results 
showed a clear increase in Pac-induced expression of Fas receptor, which was abrogated 
by addition of Dex. Changes in were quantified by densitometry showing a high 
statistical significance (p=<0.0001) between vehicle control and Pac-treated cellular 
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levels of Fas (Fig. 3.5C; right panel). Dex also abrogated Pac-induced expression of Fas 
to a statistically very significant degree (p=<0.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  80	  
	  
Figure 3.5 
3.5A. 
            
 
3.5B. 
           
 
	  81	  
	  
3.5C. 
                 
 
Figure 3.5 FASLG and FAS are upregulated by Pac and down-regulated by Dex. 
A. and B. TNBC breast cancer cell lines MDA-MB-468, Hs578t, and MDA-MB-231 
cells were treated with  vehicle (NT),  Dex, Pac, or co-treated Dex and Pac (Dex 1 h prior 
to Pac) for 24 h. Quantitative real-time PCR analysis of FASLG and FAS mRNA are 
expressed as relative fold change compared to control (NT) following normalization to 
GAPDH. C. Hs578t cells were treated with vehicle (NT), Dex, Pac, or co-treated with 
Dex and Pac (Dex 1 h prior to Pac) for 24 h to be examined for Fas levels by subjecting 
the whole-cell lysates to SDS-PAGE. Densitometry of n=3 is shown in the right panel.  
Represented data are mean ± SEM of at least three individual experiments. *p ≤ 0.05, **p 
≤ 0.01, ***p ≤ 0.001. 
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3.3.6 Knock-down of FASLG desensitizes breast cancer cells to Pac-induced 
apoptosis. 
 FasLG is a transmembrane protein that binds Fas receptor to initiate cellular death 
pathways [22]. To assess the significance of FasLG/Fas receptor signaling in mediation 
of Pac-induced apoptosis and Dex-mediated rescue of breast cancer cells from Pac we 
stably infected MDA-MB-468 cells with a sh FASLG construct. The extent of FASLG 
knock-down was measured by quantitative real time PCR (qRT) of FASLG mRNA 
levels. Knock-down of FASLG was observed at 89.8% decrease in mRNA levels 
compared to the sh Scramble control infected parental cell line (Fig. 3.6A). Knock-down 
of FASLG significantly impaired the ability of Pac to decrease total viable cell numbers 
(14.6% decrease in total cell number) compared to sh Scramble parental cells (51.3% 
decrease in total cell number) (Fig. 3.6B). Moreover, the ability of Dex to rescue cells 
from Pac is greatly mitigated by the knock-down of FASLG. Dex increased total cell 
number when pre-administered to Pac-treated cells by 41.2% compared to a rescue of 
only 5.22% in sh FASLG cells (Fig. 3.6B). 
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Figure 3.6 
3.6A. 
 
3.6B. 
 
Figure 3.6 Essentiality of FasLG/Fas signaling in sensitivity of breast cancer cells 
to Pac. 
A. Expression of FASLG in MDA-MB-468 cells stably infected with sh FASLG was 
analyzed using real-time PCR. The relative expression level of FASLG in the knock-
down sample is calculated as relative fold change compared to control. B. Stable sh 
Scramble or sh FASLG cells were treated for 24 h with vehicle, Dex, Pac, or co-treated 
with Dex and Pac. Cells were collected and counted for total cell number. Data are 
represented as mean value ± SEM of at least three individual experiments. *p ≤ 0.05, **p 
≤ 0.01, ***p ≤ 0.001. 
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3.3.7 Fas receptor transcription is downstream of Pac-activated NFκB  
While both FASLG and FAS expression increased following Pac treatment (Figs. 
3.5A and 5B) Dex was unable to suppress FASLG expression during co-treatment with 
Pac suggesting the possibility of different mediators of Pac-induced transcriptional 
regulation for each gene. Moreover, the inhibition of NFκB activity by Dex (Fig. 3.3B) 
does not necessitate that Dex down-regulates FAS by inhibition of NFκB. To ensure FAS 
transcriptional regulation by Pac is directed through activation of NFκB we treated sh 
Scramble, sh p50 and sh p65 cells with and without Pac for 24 h. Cells were collected 
and mRNA for FAS was quantified by qRT (Fig. 7). The sh Scramble stable cells show a 
significant increase in FAS expression (p=0.0031) (Fig. 3.7). The knock-down of p50 
protein, which also significantly decreased p65 levels (Fig. 3.4A), resulted in much less 
expression of FAS following Pac treatment with no significant change in Pac-treated sh 
NFκB cells relative to the non-treated control (p=0.2687) (Fig. 3.7). By knock-down of 
the p65 protein, FAS levels did not significantly increase following Pac treatment 
compared to vehicle (NT) controls (p=0.2646) (Fig. 3.7).  
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Figure 3.7 
 
Figure 3.7 NFκB is essential for Pac-mediated transcriptional upregulation of 
FAS. 
Sh Scramble, sh p50, and sh p65 cells were treated with the vehicle or Pac for 24 h. Cells 
were collected and their total RNA was subjected to real time PCR. Expression levels of 
FAS were normalized to GAPDH and presented as fold relative to the control. 
Represented data are mean ± SEM of three individual experiments. *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001.  
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3.4 Discussion 
 Pac is a potent anti-cancer drug often reserved for TNBCs and as a last line of 
defense against late stage luminal cancers or those that display resistance to traditional 
therapies. Side-effects of Pac, and the vehicle in which it is dissolved (Kolliphor EL), are 
counteracted by administration of synthetic GCs such as Dex. Dex is often given hours 
before chemotherapy, and often administered even multiple times per day. Despite the 
tremendous efficacy of Pac as an anti-cancer drug, there are increasing reports indicating 
that co-treatment with Dex antagonizes Pac in several solid tumour cell lines [23-25].  
 To elucidate the effect of Dex pre-treatment on Pac-induced cell death in breast 
cancer cells, and the underlying mechanism, we established an in vitro set-up in which 
Dex was administrated to cells 1 h prior to Pac [6]. This setting not only imitates the most 
common clinical application of Dex, but also shows the extent of its protective role even 
when given once immediately prior to chemotherapy. Our observations in this study 
support that Dex pre-treatment antagonizes Pac-induced cell death by abrogation of 
FAS/FASLG expression via the NFκB transcription factor. Initially, we resolve the 
sensitivity of various breast cancer cell lines, both TNBCs (MDA-MB-468, Hs578t, and 
MDA-MB-231) and luminal (MCF 7, SK-BR-3, and T47D) to Pac alone (Fig. 3.1). 
While all showed sensitivity to Pac, on average, the TNBCs were much more responsive 
than the luminal cell lines. Our data now supports that the observed differential resistance 
between TNBCs and luminal breast cancer cell lines may be due to altered regulation of 
NFκB in luminal cells, as was previously reported [18]. We show that sensitivity of each 
respective cell line to Pac alone was matched by their likelihood for Dex-mediated rescue 
from Pac, demonstrated by statistically significant increases in viable cell number of 
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TNBCs (Figs. 3.2A and 2B). Our data also supports that sensitivity to Dex-mediated 
rescue from Pac may be due levels of GR being highest in the TNBCs, making TNBCs 
more primed for Dex-mediated action. Therefore, we hypothesized that pre-treatment of 
TNBCs with the GR antagonist mifepristone (RU-486) should decrease the likelihood of 
Dex-mediated rescue from Pac (Fig. 3.2C). When tested, addition of RU-486 to co-
treated Pac and Dex MDA-MB-468 cells significantly reversed the Dex-mediated effects, 
which corroborates reports that pre-medication of RU-486 with GCs can be an alternative 
solution to block the proliferative/survival effects of Dex and increasing Pac-induced 
apoptosis in TNBC patients [26]. As suggested by others, Dex treated cells generally 
showed increase in cell number (Figs. 3.2A and 2B), however, we show that Dex-
mediated rescue from Pac could primarily be mediated through inhibition of Pac-induced 
apoptosis (Fig. 3.2D). 
 GCs are known to exhibit adverse pleiotropic effects in a cell-type dependent 
manner [2]. While the precise mechanism of GC-induced resistance to Pac is a 
developing story, it may be associated with multiple pathways depending on the cell type 
[27]. Regardless, our data supports that Dex-mediated resistance to Pac is mediated 
through, at least in part, the control of gene expression [28]. Regulators of NFκB, in 
particular IκBα, have been shown to play a part in biological activities such as apoptosis, 
and to also be regulated by Pac [18]. Here, we successfully show that Pac promoted 
NFκB activation in different breast cancer cell lines, and that this activation was 
dampened by pre-treatment with Dex (Fig. 3.3). Our data supports the claim that the 
antagonistic effects of Dex and Pac might be through their oppositional regulation of the 
NFκB pathway. Knock-down of NFκB subunits, p50 and p65, desensitized the cells to 
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Pac-mediated apoptosis (Fig. 3.4). While Pac treatment reduced cell viability by more 
than 50% in control cells, stable knockdown of p50 and p65 we resulted in diminished 
sensitivity to Pac with decreases of only 6.21% and 38.6% respectively. It is not entirely 
surprising that Pac continues to cause some level of apoptosis even with substantial 
knock-down of NFκB given that it is a potent cytotoxic drug activating numerous cellular 
responses that directly or indirectly activate various programmed cell death responses. 
Our data supports NFκB being among the list of potent mediators of Pac-induced 
apoptosis.  
 While NFκB transcriptionally regulates a number of genes involved in cell survival 
signaling, it also regulates two prominent activators of apoptosis: FASLG and FAS [29]. 
In this study, expression of both genes, FASLG and FAS, were down-regulated by Dex 
and upregulated by Pac (Fig. 3.5). However, only Pac-induced upregulation of FAS was 
significantly obstructed by Dex in co-treatment conditions. Given our finding that 
FasLG/Fas signaling is a potential mediator of Pac-induced apoptosis in TNBCs, we 
knocked down FASLG. Cell counts following treatment with Dex and Pac showed nearly 
50% reduction in viable cell number whereas knock-down of FASLG exhibited only 
14.6% decrease in total viable cell number (Fig. 3.7B). Thus, the ability of Dex to 
antagonize Pac requires activity of the FasLG/Fas pathway. We also found that knock-
down of NFκB subunits attenuated FAS expression to the point that no statistically 
significant increase in expression occurred (Fig. 3.7), which strongly supports that the 
transcriptional regulation of Pac-induced FAS is a mediated through NFκB. 
 In summary, Dex significantly diminishes Pac-induced apoptosis in breast cancer 
cell lines of luminal and TNBCs subtypes. Inhibition is most significant for the TNBCs 
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for which Pac is a primary therapeutic agent. Our data adds to the mechanistic 
information available describing this phenomenon (Fig. 3.8). We show that Pac and Dex 
contrarily regulate NFκB and Dex is able to abrogate Pac-mediated activation of NFκB. 
Furthermore, knock-down of the subunits of canonical NFκB (p50/p65) densensitizes 
TNBCs to Pac supporting that NFκB signaling plays a critical role in Pac-mediated 
apoptosis in these cell lines. While Pac and Dex contrarily regulate gene expression of 
FASLG and FAS, only FAS expression is overridden by Dex under co-treatment 
conditions with Pac and is corroborated at the protein level. We show that FasLG/Fas 
signaling is a critical component of Pac-induced apoptosis in these cells as knock-down 
of FASLG desensitizes cells to Pac. Finally, Pac-mediated regulation of Fas is through 
NFκB as knock-down of the NFκB subunits mitigates Pac’s ability to upregulate FAS. 
Collectively this work adds to the body of growing knowledge that GCs such as Dex 
override breast cancer responses to chemotherapy. These data may have important 
implications for patient outcomes in the clinic and need to be further explored in clinical 
trials. 
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Figure 3.8 
 
 
Figure 3.8 Dex and Pac contrarily regulate Fas signaling through NFκB 
regulation. 
A general depiction of Pac and Dex regulation of Fas expression through the NFκB 
signaling pathway. See text for detailed explanation of pathway. D: Dex; P: Pac. 
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Chapter 4: General discussion and future directions  
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4.1 Overview 
 Breast cancer is the most prevalent form of cancer to affect Canadian women with 
approximately 24,000 new cases each year [1].  Approximately 30% of women with 
breast cancer will develop metastatic disease for which there is no cure [2,3]. Progression 
to a metastatic state from the primary tumor site requires tumor cells to possess unique 
characteristics allowing them to 1) elude apoptosis and to grow and proliferate at the 
primary tumor site; 2) invade through existing tissue membrane boundaries; 3) migrate in 
circulation, or within neighbouring tissues, and 4) attach and colonize at a distant site [4]. 
These characteristics may be inherent in certain subpopulations of breast cancer cells, 
they may be acquired through mutation(s), or drug treatment of cancer cells may promote 
these characteristics [3].  
 Breast cancers are categorized histologically into luminal and triple negative 
(TNBCs) subtypes based on hormone receptor status [5-7]. The absence of these 
hormone receptors in TNBCs creates difficulty in clinical treatment. TNBC patients, 
along with late stage and hormone-resistant luminal breast cancer patients, commonly 
receive paclitaxel (Pac) [8,9]. Pac and the vehicle it is dissolved in, however, frequently 
cause hypersensitivity, nausea, vomiting, and allergic reactions in patients [10-12]. To 
counteract these reactions, the synthetic glucocorticoid dexamethasone (Dex) is 
administered hours and sometimes days in advance of Pac. Dex is a potent activator of 
the glucocorticoid receptor (GR) which regulates either negatively or positively 
approximately 10% of the human genome [13]. Given the pleiotropic effects of Dex in 
numerous tissues, we assessed the impact of Dex both in vitro and in vivo on breast 
cancer survival/proliferation, migration and invasion.  
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 We demonstrate that administration of Dex increases cell number within 24 h 
post-treatment relative to vehicle-treated control cells in vitro (Figs. 2.2A and 2B). 
Sensitivity to Dex-mediated increases in cell number correlates with breast cancer 
subtype. It remains unclear, however, as to whether or not Dex-mediated effects are due 
to increased proliferation, survival or a combination of both. We demonstrate, using 
apoptosis assays, that Dex downregulated the activity of apoptotic proteases Caspase 3 
and 7 compared to control and in co-treatment conditions with Pac compared to Pac alone 
(Figs. 2.2D and 2E). It remains to be determined how much of the decrease in caspase 
activity accounts for the difference in total live cell number of the Dex-treated population 
versus control population. Nevertheless this decrease in caspase activity is consistent with 
a Dex-induced pro-survival role. As the question at hand was to determine whether or not 
Dex could enhance a critical characteristic of metastatic breast cancer cells (i.e. survival 
and growth), we demonstrate in the affirmative that it does. Clarification on the matter of 
Dex-mediated cell survival versus Dex-mediated proliferation could be produced by 
performing bromodeoxyuridine (BrdU) incorporation assays; alternatively, antigen Ki-67 
expression could be measured to see if changes in proliferation are occurring. Also, 
further corroboration of Dex-mediated increases in cell number could be produced by 
treating cells with vehicle control, Dex alone and or Dex + RU-486 supporting the 
conclusion that active GR is responsible for the Dex-mediated effects. 
 In regards to in vitro increases in cell migration and invasion we show that Dex 
causes overall cell motility as migration through cyto-select chambers and invasion 
through collagen coated chambers greatly increased following Dex treatment (Figs. 2.3 
and 2.4). A legitimate concern is that apparent increases in migration and invasion might 
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be false positives due to increases in overall cell number. We performed experiments to 
address two possible alternative explanations for the observed migration and invasion 
phenotype, in particular: 1) whether Dex-treated cells could proliferate or survive better 
in the serum-free conditions over the 24 h period of the assay or 2) that Dex-treated cells 
had proliferative pathways activated such that when they migrated or invaded to complete 
growth media conditions they had a proliferative advantage (e.g., a head start) compared 
to those cells that migrated or invaded in control chambers.  To test the first alternate 
explanation Dex effects on overall cell number were tested in the serum-free conditions 
(mimicking pre-migration side of chamber) over the full 24 h period mimicking the 
length of the migration and invasion assays (Figs. 2.3D and 3E). The Dex treated 
chambers did not have more cells in them to migrate compared to vehicle control cells, 
hence enhanced proliferation of the cells in the pre-migration chamber did not explain the 
migration/invasion assay results. To test the second alternative explanation, we grew cells 
in serum-free conditions with vehicle or with Dex for 24 h and then replaced their media 
with complete growth media lacking Dex (mimicking a condition in which the cells had 
migrated or invaded). Dex-treated cells did not show an increase cell number in complete 
media within 24 h of changing media from serum-free to complete (Fig. 2.3D and 3E). 
We did observe, however, increases in MDA-MB-231 cell number compared to control 
populations if Dex-treated cells were allowed more time (48 h) in growth factor positive 
conditions (Fig. 2.3D). Thus, it would appear that not only does Dex increase cell 
motility, but Dex-treated cells that invade or migrate eventually either proliferate faster, 
or survive better following movement, than non-Dex-treated cells.  
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 One other matter of concern to address is how do we explain having observed 
increases in cell number in Dex-treated cells compared to vehicle controls cells earlier 
and then claim such does not occur in the same time-period during the migration and 
invasion assays? Increases in cell number demonstrated earlier (Fig. 2.2) were in 
complete media conditions in which growth factors are present throughout the 
experiment compared to the serum-free conditions of the migration and invasion assays 
in which growth factors are only available to cells that cross the membrane. Thus, it is 
true that Dex enhances cell numbers compared to vehicle-treated control, but this 
phenotype is not observed in the early stages of the migration/invasion assays which last 
for a short period of time and are conducted in serum-free conditions. Overall, the 
implication for breast cancer patients is that multiple metastatic characteristics could be 
enhanced by Dex treatment in clinic. 
 Our data also demonstrates that Dex mediates overall metastatic properties of 
human breast cancer cells in vivo using a zebrafish model (Fig. 2.5). We demonstrate that 
Dex-treated fish have more cancer cells at greater distances from initial injection sites 
than control fish. Which cell behaviour is responsible for this physiological effect needs 
to be carefully dissected. It is possible that increased proliferation or survival in the yolk 
sack of Dex treated fish could increase the likelihood of increased cells at distant sites. 
Alternatively, increased migration or invasion could also explain the increased number of 
distant site cells in Dex treated fish. Increases in proliferation or survival of inherently 
invasive or migratory cells after invasion from the yolk sack could also explain the 
difference between Dex-treated and control fish. Nonetheless, the phenotype of increased 
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numbers of viable cells at distant sites holds true for Dex-treated fish relative to control 
fish. These observations warrant further research into the matter of concern at hand. 
 Some might argue that the impact of Dex on the proliferation, or invasiveness, or 
migratory capacity of breast cancer cells is of no concern as these patients ultimately 
receive the potent cytotoxic drug Pac. We sought to further previous work on the topic of 
Pac-resistance in Dex-treated breast cancer cells. We sought to assess the prevalence of 
this phenotype in breast cancer cells lines representative of TNBC and luminal breast 
cancers, and to elucidate a mechanism by which Dex might mediate its pro-survival role 
against Pac. 
 We demonstrate that Dex does protect breast cancer cells from Pac, in particular 
from Pac-induced apoptosis. We also find that overall TNBCs were more sensitive to Pac 
than luminal cell types, encouraging given that TNBCs are highly dependent on Pac for 
treatment. However, Dex induced a strong rescue in both subtypes as demonstrated by 
inhibition of caspase 3 and 7 activity. One anomaly with the luminal cell lines (SK-BR-3 
and T47D) was that Dex’s rescue from Pac activation of caspases 3 and 7 (Fig. 3.2D) was 
inconspicuous in the total live cell number (Fig 3.2B). This phenotype may suggest an 
alternative means of Pac-induced death that does not involve activation of caspase 3 and 
7. 
 Previous work had demonstrated that NFκB signaling could play an important 
role in Pac-induced apoptosis. An upstream regulator of NFκB, MAP3K1, is 
transcriptionally upregulated following Pac treatment [14,15]. MAP3K1 phosphorylates 
IKKβ1 resulting in phosphorylation and subsequent degradation of IκBa [14,15]. 
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Unphosphorylated IκBα sequesters NFκB in the cytoplasm. Huang et al show that 
transcriptional upregulation of IκBα is important in mediation of Dex-inhibition of Pac. 
We identify the downstream target of Pac-induced NFκB as Fas receptor (Fas). While 
both Fas ligand (FasLG) and Fas are transcriptionally upregulated following Pac 
treatment, and both are transcriptionally down-regulated by Dex-alone treatment, only 
Pac-induced Fas transcription was antagonized following co-treatment of Dex and Pac. 
Knockdown of the p50 and p65 subunits of NFκB diminished Pac transcriptional 
upregulation of Fas, putting Fas signaling downstream of Pac-activated NFκB. Thus, the 
overall pathway would be as follows in the absence of Dex: Pac, through an unknown 
mediator causes transcriptional upregulation of MAP3K1. MAP3K1 phosphorylates and 
activates IKKβ1. Active IKKβ1 phosphorylates IκBα and marks it for ubiquitination and 
degradation by the 26S proteasome complex. Following degradation of IκBα NFκB 
translocates to the nucleus where it binds promoter element in the FAS gene. 
Upregulation of FAS (and FASLG by another Pac-mediated pathway), results in eventual 
activation of the extrinsic pathway of apoptosis. In the presence of Dex transcriptional 
upregulation of IκBα could saturate IKKβ1 activity leaving residual IκBα protein to 
sequester a portion of NFκB complexes in the cytoplasm. Pac’s activation of NFκB 
would be partially attenuated by the diminished NFκB transcriptional activity and 
subsequent diminished upregulation of the extrinsic pathway mediator Fas.  
 Overall our work shows that the administration of Dex to breast cancer patients 
could increase negative characteristics of metastatic breast cancer cells even within the 
early hours of treatment. Given that Dex also protects breast cancer cells from Pac-
induced apoptosis it may be that not only a greater number of breast cancer cells survive 
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chemotherapy, but also that those cells are made more dangerous in the process. 
Nevertheless, there remains work to be done to better understand these reported effects of 
Dex on breast cancer cell behaviour. Such future studies could include both immediate in 
vitro and in vivo laboratory work as well as longer term clinical trials. 
4.2 Future Directions 
 Several short-term immediate in vitro assays could provide clarity concerning the 
impact of Dex on breast cancer cell behaviour. Repeating the cell counts, as well as the 
migration and invasion assays with the addition of a Dex + RU-486 treatment would 
falsify or corroborate the role of the GR in mediating the reported effects. Moreover, 
since previous reports of Dex’s impact on these same phenotypes in other cell lines 
differed in response, when compared to the breast cancer cell lines use herein, the 
addition of other such cell lines (e.g., bladder cancer cell lines) could serve as positive 
controls against which we could compare our reported findings [16]. Dosing and timing 
of Dex and/or Pac treatment were consistently conducted for all experiments with Dex 
being administered at 1 µM and given one hour in advance of Pac (0.1 mM) during co-
treatment experiments. These doses and timings were based on previous reports in the 
literature as to being the most clinically relevant [17]. For several experiments (primarily 
those involving Dex alone) numerous concentrations of Dex were used although we 
strove to ensure that for each cell line Dex (1 µM) was a common treatment. It could 
prove valuable to use various concentrations of Dex and Pac as well as alternate timings 
of delivery to determine if the impact of Dex on Pac is dose/timing dependent. Such data 
could be useful for altering clinical protocols so as to maximize the efficiency of Pac 
while minimizes the pro-survival role of the anti-emetic Dex. Furthermore, breast cancer 
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patients do not receive Paclitaxel alone but rather a cocktail of antineoplastic drugs. 
Replicating the order, timing and dosages of these drugs in the presence and absence of 
Dex would demonstrate the potency or impotence of Dex to antagonize chemotherapy on 
these breast cancer cell lines. 
 In terms of the in vivo assays performed herein, other model organisms such as a 
mouse model could strengthen the results observed in the zebrafish. For example, breast 
cancer cells (TNBC, e.g., MDA-MB-231 and luminal, e.g., MCF 7) could be transplanted 
for xenograft studies into the mammary fat pad of female severe compromised immune-
deficient mice (SCID). Once tumours form and reach approximately 200 mm3 the mice 
could be treated with vehicle, Dex or Dex and RU-486. The longest and shortest 
diameters of the tumours would be measured by calipers several times a week and tumour 
volume calculated. There are several advantages and disadvantages to using the mouse 
model compared to the zebrafish model. Similar to the zebrafish (which lack an immune 
system up to day 14), the SCID mice lack an immune system [18]. The absence of the 
immune system gives the technical advantage of establishing cancer cells without 
immune system-mediated detection and destruction. In mice the absence of the immune 
system makes interpretation of the relevance of the observed data more difficult for 
cancer in humans with an intact immune system, where as the zebrafish immune system 
develops at maturity. The mouse model provides the advantage of being a mammalian 
model system with a mammary gland, allowing for orthotopic injections, however, there 
remain differences between mouse mammary glands and human mammary glands. For 
example, human cells are not as well adapted for the mouse mammary environment. A 
recent report shows that breast cancer metastasis to bone in which the target organ is of 
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human origin, the cancer cells preferentially migrate and colonize the bone of human 
origin, thus exhibiting selective preference [19].  
 Despite reports of the Dex’s ability to antagonize Pac, to date there have been no 
clinical trial studies to compare the anti-cancer efficiency of Pac in the presence and 
absence of Dex. Such a trial would be of high clinical relevance to patients. Currently all 
patients receiving Pac are co-treated with Dex, with some patients receiving several doses 
of Dex prior to chemotherapy treatment. Dex is administered to block the undesired 
emetic effects of Pac but many of these effects are due to the delivery vehicle Pac is 
dissolved in, namely castor oil [10]. Alternate forms of Pac, Abraxane, now exist where 
the drug is fused to serum albumin and not dissolved in castor oil, lowering the need for 
anti-emetics. Clinical trials using traditional Pac and Abraxane in the presence and 
absence of Dex could address both the differences as to the efficiency of the alternate 
delivery systems and whether or not Dex is even needed with Abraxane. Clinical trials 
could yield both early results, such as overall tumour response (as measured by changes 
in tumour volume) as well as long-term result data, e.g., disease-free state, etc. Our data, 
and that of others, strongly support the need for a direct clinical trial to be performed; 
Abraxane provides a very nice alternative that could be used and studied in the presence 
and absence of gluocorticoids for this purpose.   
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